

Progress towards a biotypic biomarker profile for amyotrophic lateral sclerosis–frontotemporal spectrum disorders

Michael J. Strong,^{1,2,3} Neil Donison,¹ Ammar Al-Chalabi,⁴ Bradley Boeve,⁵ Elizabeth C. Finger,^{2,6} Henne Holstege,^{7,8} Edward D. Huey,⁹ Edward B. Lee,¹⁰ Sarah J. Marzi,^{4,11} Caroline McHutchison,¹² Corey T. McMillan,¹³ Markus Otto,¹⁴ Leonard Petrucelli,¹⁵ Mercedes Prudencio,¹⁶ Tanya Simuni,¹⁷ Maria Carmela Tartaglia,^{18,19,20} Martin R. Turner,²¹ Philip Van Damme^{22,23} and David A. Wolk²⁴

Abstract

Determining the optimal timing of disease-modifying therapies for neurodegenerative disorders will necessitate identification of when the underlying pathobiological process becomes active, well in advance of the point at which clinical manifestations appear. Phenoconversion, the emergence of clinically manifest syndromes, may be preceded by years to decades of silent pathobiological activity that can only be mapped by an array of biomarkers.

ALS and FTD, traditionally identified as distinct clinical syndromes, are increasingly recognized to exist along a spectrum of clinical syndromes with shared genetic risk and shared underlying pathology. This clinicopathological spectrum is underpinned by cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP-43) as the common neuropathological hallmark. In contrast, the majority of neuropathologically-defined frontotemporal lobar degeneration (FTLD) is associated with alterations in either TDP-43 metabolism (FTLD-TDP) or of the microtubule associated protein tau (FTLD-tau), with a smaller percentage associated with either autosomal dominant genetic mutations or impairments in the ubiquitin proteasome system. As the field of neurodegenerative disorders increasingly shifts towards the frameworks of a pathobiological definition of disease, there is a growing imperative to develop biomarkers that reflect the varied pathobiologies that underly these disorders, and to determine the sensitivity of such biomarkers to detect the presence of these pathobiologies before phenoconversion.

© The Author(s) 2026. Published by Oxford University Press on behalf of The Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

To that end, an international workshop was convened in London, Canada in 2025 to review the evidence for existing or evolving biomarkers suitable for (1) the detection of either ALS or FTD pathobiology prior to phenoconversion and/or (2) predict phenoconversion in at risk individuals. Such biomarkers might be conceptualized as “biotypic biomarkers”, capturing their ability to describe an underlying pathophysiology whilst being agnostic to the emergent clinical manifestations. Whereas no single biotypic marker is yet able to predict the emergence of ALS, FTD or their intersection, a multimodal approach to developing a biotypic biomarker profile holds promise for the detection of relevant pathobiological processes. The strength of such an approach would be augmented by also addressing issues of resiliency/susceptibility both in terms of genetic risk susceptibility profiles and developing sensitive biomarkers of genomic and cellular aging. By including such nontraditional markers of disease, a more robust picture of not only the degenerative process but also of those factors that might potentially mitigate or drive a heightened probability of disease can be derived.

Author affiliations:

1 Molecular Medicine Group, Robarts Research Institute, Schulich School of Medicine & Dentistry, Western University, London, Canada, N6A 3K7

2 Department of Clinical Neurological Sciences, Schulich School of Medicine & Dentistry, Western University, London, Canada, N6A 5A5

3 Department of Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, Western University, London, Canada, N6A 5C1

4 Department of Basic and Clinical Neuroscience, King's College London, London, SE5 9RT UK

5 Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA

6 Department of Cognitive Neurology, St Joseph's Health Care London, London, ON, Canada N6C 0A7

7 Alzheimer Centre Amsterdam, Amsterdam University Medical Centers, 1081 HZ Amsterdam, The Netherlands

8 Department of Clinical Genetics, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands

9 Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI 02912, USA

- 10 Center for Neurodegenerative Disease Research, Department of Pathology and
Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania,
Philadelphia, PA 19104-2676, USA
- 11 UK Dementia Research Institute at King's College London, London, SE5 9RT, UK
- 12 Division of Psychology, University of Stirling, Stirling, FK9 4LA, UK
- 13 Department of Neurology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, PA 19104, USA
- 14 Department of Neurology, Martin-Luther-University Halle-Wittenberg, 06120 Halle
(Saale), Germany
- 15 Department of Neurology, University of Miami School of Medicine, Miami, FL 33136,
USA
- 16 Department of Biochemistry and Molecular Biology, University of Miami School of
Medicine, Miami, FL 33136-1019, USA
- 17 Department of Neurology, Northwestern University Feinberg School of Medicine,
Chicago, IL 60611, USA
- 18 University Health Network, Toronto, ON, Canada M5G 2C4
- 19 Toronto Western Hospital, Tanz Centre for Research in Neurodegenerative Disease,
Toronto, ON, Canada M5T 0S8
- 20 Division of Neurology, Toronto Western Hospital, University Health Network, Toronto,
ON, Canada M5T 2S8
- 21 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU,
UK
- 22 Laboratory of Neurobiology, Department of Neurosciences, Leuven Brain Institute (LBI),
KU Leuven - University of Leuven, O&N5 Leuven, Belgium
- 23 Department of Neurology, University Hospitals Leuven, 3000 Leuven, Belgium
- 24 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA19104, USA
- Correspondance to: Michael J. Strong, MD
- Robarts Research Institute, University of Western Ontario, 1151 Richmond Street, London,
Ontario, Canada N6A 3K7

E-mail: mstrong@uwo.ca

Running title: Biotypic biomarkers in ALS-FTSD

Keywords: cryptic exons; cryptic proteins; cytoskeletal proteins; neurofilaments; neuroinflammation; epigenetics; telomere

ORCID numbers

Ammar Al-Chalabi	0000-0002-4924-7712
Brad F Boeve	0000-0002-4153-8187
Neil Donison	0000-0001-8630-7481
Elizabeth Finger	0000-0003-4461-7427
Henne Holstege	0000-0002-7688-3087
Edward Huey	0000-0002-8295-5884
Edward Lee	0000-0002-4589-1180
Sarah Marzi	0000-0002-3924-2053
Caroline McHutchison	0000-0003-0103-8580
Corey T McMillan	0000-0002-7581-6405
Markus Otto	0000-0003-4273-4267
Leonard Petrucelli	0000-0003-2959-129X
Mercedes Prudencio	0000-0002-4894-4858
Tanya Simuni	0000-0002-2347-1644
Michael Strong	0000-0003-1988-6262
Carmela Tartaglia	0000-0002-5944-8497
Martin R Turner	0000-0003-0267-3180
Philip Van Damme	0000-0002-4010-2357
David Wolk	0000-0002-3554-3481

Introduction

As our understanding of the pathophysiological basis of amyotrophic lateral sclerosis (ALS), the frontotemporal dementias (FTD) and their intersection as the ALS frontotemporal spectrum disorders (ALS-FTSD) evolves, so too does the impetus to define each in terms of their respective biologies as opposed to discrete clinical entities¹. To address this, thought leaders in each field convened in London, Canada in the spring of 2025 to examine whether the biological understanding of these disorders was sufficiently advanced to allow for the detection of a disease state prior to it becoming clinically manifest (phenoconversion). The impetus for this was, in part, the recognition that ALS and FTD are likely characterized by long subclinical latency that manifests only after some threshold of biological disease

burden has been crossed. While such latencies are likely variable, the ability to detect the presence of pathophysiologically relevant disease processes during the clinically silent and prodromal periods prior to phenoconversion will be critical as disease-modifying therapies for these disorders advance.

Doing so however presents a unique challenge in that the clinical and neuropathological intersection of ALS and FTD suggests that identifying a single biomarker that will reflect the core biology or biologies of these diseases will be unsuccessful. Because of this challenge and recognizing that current terminologies regarding biomarker classification are evolving, we have borrowed from recent advances in defining specific subgroups of psychosis. These use the terminology of biotypic biomarkers to specifically address biological markers that describe an underlying pathophysiology while being agnostic to the clinical manifestations or the different contexts of use of biomarkers as recognized by the BEST guideline (Biomarkers, EndpointS, and other Tools)²⁻⁴. The advantage of such an approach is the incorporation of a broad array of information in creating a biomarker profile that first and foremost characterizes the presence of a biological disease state well before it is clinically evident. There is precedent for such an approach for carriers of autosomal dominant mutations in *APP*, *PSEN1* and *PSEN2* in the detection of active pathobiological processes prior to phenoconversion to Alzheimer's disease (AD)⁵. In this, meaningful temporal mapping of the pathobiological activity underlying clinically silent AD can be accomplished using a suite of pathophysiologically relevant biomarkers that included measures of amyloid (A β) and tau deposition (AD relevant phospho-tau species), neuronal degeneration [microtubule associated tau protein (total tau; t-tau)] and axonal degeneration [neurofilament light chain (NFL)], alongside measures of synaptic degeneration (beta-synuclein), neuroinflammation, brain atrophy (magnetic resonance imaging; MRI) and cognition.

Such a multimodal biotypic biomarker profile by its nature is designed to inform the presence of a pathobiological process, but also allows for the incorporation of key factors such as markers of disease resiliency and susceptibility. The latter is relevant in that neurodegenerative diseases do not exist in genetic isolation but rather occur on a background of genetic risk factors [both monogenic and polygenic, including single nucleotide variants (SNPs) and epigenetic modifiers of gene expression] that may "heighten" the probability of disease induction. There are also genetic constructs that might "protect" an individual from the ravages of age-dependent neurological disorders and allow for longevity reaching well into the decades beyond traditional median ages of death – the superaging cohorts. Environmental exposures can additionally contribute to disease susceptibility; for example, up 45% of AD risk has been associated with modifiable factors such as education and air pollution⁶. While these are often categorized as

susceptibility/risk biomarkers, it can be strongly argued that they can also contribute to a biotypic biomarker profile.

One of the primary areas of focus for the symposium was an examination of whether the current suite of biomarkers for ALS, ALS-FTSD or FTD is sufficiently robust to permit detection of an active disease process during a stage of clinical silence and also predict phenoconversion. While biomarkers can also be utilized for prognostication, disease staging and the detection of a therapeutic response among those with clinically manifest disease, these latter entities have been critically reviewed elsewhere and were not the focus of the workshop⁷. Another limitation was the intentional minimal focus on biomarkers of imaging, electrophysiology and clinical outcomes (e.g., cognition, behaviour and signs of neuromuscular dysfunction) in the belief that this grouping of biomarkers would be deserving of a separate workshop for logistical reasons and robustness of discussion. As will be discussed, however, ultimately any biomarker suite will need to be inclusive of these critical modalities.

TDP-43 proteinopathies

Transactive response DNA-binding protein 43 (TDP-43) proteinopathies are a heterogeneous group of neurodegenerative disorders characterized pathologically by the presence of aberrant cytosolic aggregation with nuclear TDP-43 depletion, predominantly in the central nervous system although TDP-43 deposits or pathological phosphoTDP-43 (pTDP-43) isoforms have been reported in skin, peripheral blood monocytes, platelets and muscle (extensively reviewed elsewhere⁸⁻¹²).

TDP-43 is a DNA/RNA binding protein of the heterogenous nuclear ribonucleoprotein family encoded by the *TARDBP* gene. It consists of a highly structured N-terminal domain (NTD) with nuclear localization and nuclear export sequences (NLS and NES, respectively) and two sequential RNA-recognition motifs (RRM1 & 2) that assemble side by side into a positively charged groove that accommodates RNA, flanked by a glycine-rich intrinsically disordered C-terminus domain (CTD) (Figure 1)^{13,14}. The NTD regulates physiological head-to-tail nuclear TDP-43 oligomerization in solenoid-like structures that mediate DNA/RNA interactions while the CTD plays a role in alternative splicing, mRNA stability, protein-protein interactions, the formation of phase-separated RNA granules (biomolecular condensates) and in pathological cytosolic TDP-43 oligomerization. Under physiological stress, TDP-43 undergoes a nucleocytoplasmic shift to become predominantly cytosolic and associated with stress granules¹⁵⁻¹⁷. Pathological TDP-43 expression, while still characterized by this nucleocytoplasmic shift, includes TDP-43 aggregate formation that is the neuropathological hallmark in 97% of all ALS cases and all FTLD-TDP cases^{18,19}. These

condensates contain multiple RNA binding proteins (RBPs) and include highly toxic caspase-mediated TDP-43 C-terminal truncations of 25 and 35 kDa²⁰⁻²². In undergoing liquid-liquid phase separation (LLPS) as a step towards solid hydrogel condensate formation, the intrinsically disordered region (IDR) of the CTD interacts with other IDR-containing RBPs. The IDR also exhibits the greatest density of ALS-associated mutations, the presence of which increase the likelihood of TDP-43 aggregation²³⁻³⁰.

Pathological TDP-43 exhibits characteristic post-translational modifications (PTMs) that includes hyperphosphorylation, in this case particularly at serine residues 403/404 and 409/410, significantly affecting LLPS¹². The insoluble condensates are also highly ubiquitinated, a modification associated with protein degradation pathways. Although other PTMs, including acetylation, SUMOylation, poly-ADP-ribosylation (PARylation) and oxidation of cysteine residues also influence TDP-43's localization, RNA-binding ability and aggregation propensity, they have not yet been the focus of biomarker development. Complicating matters further, while pathologically phosphorylated TDP-43 with molecular masses of 45, 50 and 60 kDa can be found in ALS tissue, multiple N-terminus and C-terminus fragments are also evident, with the suggestion that these fragments may be differentially expressed within the spinal cord and brain, along with an aggregation prone acetylated isoform³¹.

A consequence of the loss of nuclear TDP-43 function includes the failure to repress the inclusion of intronic sequences, known as cryptic exons (CEs), into mature messenger RNAs (mRNAs)³². Normally, nuclear TDP-43 binds to "UG"-rich motifs in the introns flanking CEs, acting as a steric block to prevent the splicing machinery from incorporating these sequences into the final mRNA transcript. When TDP-43 is depleted from the nucleus, these CEs are de-repressed and included. The inclusion of CEs often introduces premature termination codons (stop codons) in the mRNA sequence, leading to the rapid degradation of the aberrant transcript through a quality control mechanism called nonsense-mediated decay (NMD) or to unstable RNA transcripts. This results in a functional loss of crucial neuronal proteins, such as stathmin-2 (STMN2) and UNC13A, that are vital for axon growth/regeneration and neurotransmitter release, respectively³³⁻³⁷. While less common, some CEs are spliced in-frame and escape NMD, leading to the translation of novel, aberrant proteins termed "cryptic peptides". These novel proteins, such as that derived from the gene encoding hepatoma-derived growth factor-like protein 2 (HDGFL2), are detectable in CSF³⁸⁻⁴⁰.

While primary disorders of TDP-43 include the majority (97%) of ALS cases (regardless of the presence or absence of a genetic mutation) and approximately half of FTDs, they also include a broad range of other clinical or neuropathological disorders^{8,9}. Amongst these, Limbic-predominant Age-related TDP-43 Encephalopathy Neuropathological Change

(LATE-NC) is of particular relevance to this discussion. LATE-NC is a neuropathologically-diagnosed TDP-43 proteinopathy that generally presents as an amnesic cognitive disorder with hippocampal atrophy, often in association with impairments in semantic memory while sparing other cognitive domains^{41,42}. It frequently occurs concomitantly with AD in which case the clinical phenomenology is more varied and the course more rapid.

However, the clinical correlate of LATE-NC (LATE) is commonly observed in isolation in individuals over age 65 years (> 10%) rising to over 25-40% in those aged 85 years or greater. It is significantly more frequent in APOE e4 carriers, but the degree to which this is independent of the association with Alzheimer's Disease remains to be fully clarified⁴¹⁻⁴⁴.

While the neuropathological differentiation of the most advanced variant of LATE-NC (LATE-NC Stage 3) from FTLD-TDP type A or B can prove challenging, recent advances in doing so have been made⁴⁴⁻⁴⁶.

While the vast majority of FTLDs are either tauopathies or TDP-43 proteinopathies (FTLD-tau, FTLD-TDP, respectively), a small proportion are defined by intraneuronal inclusions of TAF15 (*TAF15* encoding TATA-box binding protein associated factor 15) together with the other two FET family of RNA binding proteins [FTLD-FET; *FUS* encoding the fused in sarcoma/translocated in liposarcoma RNA binding protein (*FUS*), *EWSR1* encoding Ewing Sarcoma RNA binding protein (*EWS*)] or dysfunction of the ubiquitin proteasome system (FTLD-UPS)⁴⁷. Up to a half of all cases are familial with 10-15% inherited in an autosomal dominant manner with the majority due to monogenic mutations in the microtubule associated tau (*MAPT*) gene, the progranulin gene (*GRN*) or a pathological hexanucleotide repeat expansion of the gene encoding C9 open reading frame 72 (*C9orf72*)^{47,48}. Rare instances of autosomal dominant FTD have also been associated with genes encoding for valosin-containing protein (*VCP*), chromatin-modifying protein 2B (*CHMP2B*), TDP-43 (*TARDBP*), *FUS*, p62 (*SQSTM1*), ubiquilin 2 (*UBQLN2*), Tank-binding kinase 1 (*TBK1*) and, although potentially as a risk modifier for FTD, triggering receptor expressed on myeloid cells 2 (*TREM2*)⁴⁹. In the context of defining a biomarker profile for FTD, these genetic variants serve to define individuals at significantly elevated genetic risk.

It is perhaps not surprising, therefore, that the FTDs are a heterogeneous group of neurodegenerative diseases that share a common underlying distribution of pathology that manifests predominantly as frontal and temporal atrophy with neuronal loss and gliosis, but which can also be more widespread⁵⁰. Although the clinical heterogeneity is significant, the core clinical elements are alterations in social behaviour, personality, speech and language with additional features of corticobasal or motor dysfunction in some patients (as discussed in the companion paper Benatar et al, this issue)^{51,52}.

1 Tau proteinopathies

2 Alterations in tau metabolism in FTLD

3 As noted earlier, pathological alterations in the metabolism of the microtubule-associated
 4 protein tau (MAPT; tau) occur in approximately half of all FTLD.⁵³ Human tau is an
 5 intrinsically disordered protein consisting of 6 isoforms ranging from 352 to 441 amino
 6 acids in length, with isoforms defined on the basis of the presence of 0, 1 or 2 N-terminal
 7 domain insertions generated through alternative splicing of exons 2 and 3 (0N, 1N or 2N
 8 tau) in combination with the presence or absence of exon 10 that encodes one of the four
 9 microtubule-binding repeats (generating a 3R or 4R isoform) (Figure 2)^{54,55}. All 6 isoforms
 10 are expressed in the adult human brain with 3R and 4R expression being approximately
 11 equal⁵⁶. While the interaction of tau with microtubules is crucial for microtubule stability
 12 and axonal transport, it also has an extensive array of functions in the nucleus (protecting
 13 against DNA damage, nuclear calcium homeostasis, chromatin dynamics), mitochondria
 14 and axon (maintenance of axonal integrity, regulation of synaptic plasticity and neuronal
 15 activity)⁵⁵⁻⁶⁰.

16 Tau is a highly soluble protein predicted to adopt a paperclip-like structure in which its N-
 17 terminus domain wraps around the C-terminus domain^{61,62}. Alterations in its
 18 phosphorylation state can disrupt this structure, impeding its ability to interact with
 19 microtubules and driving it towards pathological fibril formation⁶³. These pathological
 20 fibrils are derived from soluble, low molecular weight individual tau oligomers that form
 21 protofilaments that are assembled into insoluble higher molecular weight fibrils or
 22 filaments that are unique to individual tauopathies⁶⁴⁻⁶⁶. While the oligomeric species has
 23 been proposed to be the most toxic, it is this structural arrangement of the protofilaments
 24 that provides a signature to the individual tauopathies⁶⁷. Although this level of structural
 25 specificity holds promise for the development of pathological tau biomarkers and although
 26 structurally-specific tau-PET tracers are being developed, the inability to define these
 27 structures in living patients currently limits their utility as a biomarker. Rather, this task falls
 28 to using disease-specific PTMs as highlighted by the recent deep proteomics study of
 29 Kumar et al⁶⁸ in which dementia-specific tau PTMs (both soluble and insoluble) were
 30 identified.

31 Physiological tau phosphorylation is necessary for regulating tau's function, while
 32 extensive phosphorylation at disease-specific residues can be associated with the
 33 induction of pathological tau isoforms with a heightened propensity to form β -sheet-rich
 34 oligomers, the smallest toxic species^{54,56}. For instance, the phosphorylation of tau at
 35 threonine 217 (pThr²¹⁷ tau) is relatively specific for AD and correlates with tangle burden

with elevated plasma levels broadly discriminating against FTD/FTLD⁶⁹⁻⁷³. In contrast, the aberrant phosphorylation of tau by ERK2 at Thr¹⁷⁵ (pThr¹⁷⁵ tau), a phospho-epitope not observed in controls or with aging, has been observed in neuropathological studies of ALS with cognitive impairment (ALSci), FTD-MND and many, but not all, FTD/FTLDs⁷⁴⁻⁷⁸. The phosphorylation of Thr¹⁷⁵ triggers a cascade of events resulting in the generation of pathogenic oligomeric pThr²³¹ tau⁷⁴⁻⁷⁸. Critically, regardless of the process giving rise to pThr²³¹ tau, it can exist as either *cis* or *trans* isomers with peptidyl-prolyl *cis-trans* isomerase (PIN1) driving the conversion of the aggregation-prone pathological *cis* isomer into its physiological *trans* conformation⁷⁹⁻⁸¹. Loss of PIN1 expression and activity has been associated with several neurodegenerative disease states, including AD, vascular dementia and CTE^{82,83}. However, while increases in CSF pThr²³¹ have been shown to be amongst the earliest tau biomarkers in preclinical AD alongside increases in CSF pThr¹⁸¹ and pThr²¹⁷, the more pathologically important determination of *cis* vs *trans* isomerization of pThr²³¹ tau is not readily available as a biomarker⁸⁴⁻⁸⁷. In the quest for tau biomarkers, the promise of defining unique patterns of tau transcripts, isomers, PTMs and ultimately structural species, is just beginning to fully unfold^{68,88,89}.

Alterations in tau metabolism in ALS

While over 97% of all variants of ALS demonstrate cytosolic aggregates of TDP-43 in affected neurons, pathogenic tau isoforms have been observed in both cortical and spinal motor neurons⁹⁰. A proportion of patients with ALSci, FTD (ALS-FTD) or ALS in association with chronic traumatic encephalopathy (CTE-ALS) have pathological neuronal inclusions of tau, including pThr¹⁷⁵ and pThr²³¹ tau^{75,78,91-96}. Nuclear and cytosolic immunoreactivity to pSer³⁹⁶ and cytosolic pSer²¹⁴ and pSer⁴⁰⁴ tau, modifications that can be present in both healthy and neurodegenerative disease states, has been observed in ALS cervical spinal motor neurons and cortex while only rarely observed in controls⁹⁷. Recently observed elevations in serum or plasma pThr¹⁸¹ and pThr²¹⁷ tau suggest a possible peripheral source of tau in ALS, including denervated muscle^{11,98,99}. These latter findings raise the issue that the biosample from which tau phospho-isoforms are assayed in ALS may reflect differing aspects of the disease process.

There is an increasing awareness of the co-occurrence of TDP-43 and tau proteinopathies with mounting evidence for a synergistic interaction between the two^{42,96,100-108}. For instance, the co-occurrence of AD with a TDP-43 proteinopathy is associated with greater medial temporal atrophy, faster rates of hippocampal volume loss and more severe cognitive and memory impairment with some suggestion that concomitant TDP-43 deposition may impact the disease course as early as 10 years before death¹⁰⁹⁻¹¹². At the structural level, the interaction between tau and TDP-43 appears to be direct, in part driven

by hydrogen bonds, with the interaction between full length TDP-43 and tau enhancing the formation of cytosolic TDP-43 biomolecular condensates, although tau and TDP-43 aggregates typically do not colocalize in pathologic human tissue even if they are sometimes found within the same neuron^{104,105,113,114}. With respect to the expression of 3R vs 4R tau isoforms, TDP-43 can mediate the alternative splicing of tau exon 10¹¹⁵. While these findings remain to be further explored, they raise the intriguing possibility that the intersection of ALS and FTD manifesting as ALS-FTSD is more than simply disease overlap but rather intrinsically shared pathobiology.

Blood and CSF biomarkers

This pathophysiological overlap between ALS and FTD presents as a challenge in the efforts to identify biomarkers that might discriminate between the two during clinically manifest disease, let alone in a presymptomatic state (Figure 3). Although there have been significant advances in the last several years in biomarker assay sensitivity, now reaching levels of femtomolar detection, there has been little consideration of their utility as biotypic biomarkers that are agnostic to the clinical state but rather focus on pathobiological processes (Supplementary Table 1). In the following section, using a narrative review approach, the current state of biomarkers *writ large* for the pathobiology that underpins ALS and FTD are examined individually and then collectively in the context of detecting pathophysiological dysfunction prior to phenoconversion.

Biomarkers of ALS

The use of TDP-43 as a biomarker of any type of TDP-43 proteinopathy but specifically ALS has proven challenging for several reasons, including its propensity to self aggregate, its extensive PTMs, the existence of multiple splice variants and cleavage fragments, poor CSF-plasma correlation and the marked variability between various assays (reviewed extensively elsewhere^{7,31,116,117}). While in general TDP-43 or pTDP-43 levels are found to be elevated in CSF or blood samples, the aforementioned issues drive significant variability rendering interpretation difficult^{9,118}. Suggesting a potential role in a biomarker profile, when CSF TDP-43 is evaluated in combination with one or more of CSF t-tau, pThr¹⁸¹ tau or NFL, AUC (Area Under the Receiver Operating Characteristic Curve) values were significantly improved compared to TDP-43 alone, a result not observed in combining plasma and CSF composites¹¹⁷. This latter finding held true for FTD as well¹¹⁹. At the moment therefore, direct measures of TDP-43 have not proven to be of value.

The use of t-tau or phospho-tau (ptau) as a biomarker in ALS has only recently begun to be evaluated. In a comparison study of ALS (including C9orf72 and mtSOD1) against AD and

controls using the Quanterix single molecule array (Simoa) platform, pThr¹⁸¹ tau levels were observed to be elevated in ALS plasma but not CSF with a tendency for spinal onset LMN disease to have the highest pThr¹⁸¹ tau levels⁹⁹. In a large multicentre study using the nucleic acid linked immune-sandwich assay (NULISA) CNS disease panel platform, significant increases in plasma MAPT (reflecting total tau), pThr¹⁸¹ tau, pThr²¹⁷ tau, pThr²³¹ tau and pTDP-43 that correlated with elevated NFL levels were observed in ALS patients¹²⁰. Consistent with earlier studies, pThr¹⁸¹ tau levels were highest in those patients with spinal onset⁹⁹. Also using the NULISA platform, serum levels of pThr¹⁸¹ tau and pThr²¹⁷ tau have been found to be statistically higher in ALS and AD patients than disease controls, with elevations positively associated with age and a sex effect¹¹. No differences were observed between ALS and AD serum pThr¹⁸¹ tau levels. AD patients showed higher serum levels of pThr²¹⁷ tau than ALS patients as well as higher levels of t-tau compared to both ALS and controls, the latter not being significantly different from each other. Using AUC analysis, the authors concluded that serum pThr¹⁸¹ tau could discriminate ALS from controls, but not ALS from AD, whereas pThr²¹⁷ discriminated AD from both controls and ALS.

However, the use of t-tau or ptau as biomarkers suffers from methodological issues of variability. For instance, in a number of studies, only total CSF tau and not pThr¹⁸¹ tau discriminated ALS from controls while both total t-tau and pThr¹⁸¹ tau/t-tau have been shown to be either significantly increased or decreased (respectively) compared to controls with AUC analysis for both suggesting varying degrees of sensitivity and specificity for detecting ALS¹²¹⁻¹²⁴. This variability in t-tau, pThr¹⁸¹ or pThr¹⁸¹/t-tau as reported biomarkers of ALS is complex and in part may relate to poor concordance rates between CSF and plasma values^{85,125}. For example, whereas plasma pThr¹⁸¹ tau levels have been found to be elevated in ALS patients (with proposed greater sensitivity to lower motor neuron loss) compared to controls, CSF pThr¹⁸¹ has been observed to be reduced relative to controls and AD^{99,125}. In a single study, ALS with concomitant amyloid pathology (as indicated by lower CSF A β _{42/40} ratio than ALS alone, and comparable to AD alone) showed plasma pThr¹⁸¹ levels significantly greater than ALS alone¹²⁵. This latter study also failed to show a correlation between CSF and plasma pThr¹⁸¹ values.

Perhaps more challenging in interpreting t-tau levels in ALS is a more fundamental and unexplored issue in that it is unknown the degree to which tau fragments are present in the CSF, such as that in AD¹²⁶. Linked to this, the tau amino acid (aa) sequence recognized by any given tau antibody used in the detection of CSF tau can have a significant influence on the level of tau detected¹²⁶. For example, ptau antibodies recognizing aa sequences containing pThr¹⁸¹ [aa 159 – 181 (using tau⁴⁴¹ as the reference sequence)] and pThr²³¹ (aa 159 – 231) can discriminate AD from controls although the use of a pThr¹⁸¹ antibody recognizing most of the N-terminus domain of tau (aa 9 – 181) is less discriminatory. The

method of CSF tau isolation or sample enrichment will also influence tau levels (ie., the use of direct assays vs tau enrichment through immunoprecipitation or HPLC purification). Moreover, few studies have accounted for the presence or absence of cognitive impairment, the severity of disease at the time of testing or the extent of corticospinal tract degeneration as assessed by neuroimaging measures^{123,127}. However, if the intent is to use t-tau as an indicator of an active pathobiological process driven by a loss of neuronal integrity or tau dysmetabolism (i.e., as a biotypic biomarker), then these issues are surmountable.

In contrast to assays of TDP-43 and tau, there is consistency across virtually all biomarker studies of ALS, including several systematic reviews and meta-analyses, that elevations of CSF, blood, plasma or serum NFL levels, including NFL peptides, possess a high level of sensitivity in discriminating ALS from healthy controls and ALS mimics^{11,99,117,121,124,125,127-140}. Correcting for age-adjusted increases in plasma NFL levels, both in terms of absolute levels and rate of change over time, is crucial¹⁴¹. While CSF and serum levels of NFL tend to show a high degree of correlation, in a large meta-analysis, average serum concentrations tended to be moderately (approximately 17%) higher than in plasma^{131,132,134}. It is less clear whether plasma NFL levels alone can differentiate ALS from FTD, although a recent peptidomic analysis demonstrated that elevated CSF NFL peptide levels differentiated ALS from AD, bvFTD, PD and healthy controls, albeit with small sample sizes^{135,138}.

The role of phosphorylated NFH (pNFH) as a biomarker is less clear. In general, there is a trend towards elevated CSF pNFH levels in ALS with both NFL and pNFH being able to discriminate between ALS and ALS mimics, including early in the disease course with blood or serum NFH/pNFH levels being similarly elevated albeit with somewhat greater variability^{11,130,133,136,142-144}.

Although the cellular origin of the chitinase family of proteins within the CNS remains an open question (microglial, astrocytic or both), CHI3L1 (YKL-40), Chitotriosidase-1 (CHIT1) and Chitinase-3-like protein 2 (CHI3L2 or YKL-39) are elevated in ALS CSF when compared to control cases and ALS-mimics^{121,137,145-148}. CHIT1 levels in CSF, but not serum, were significantly elevated compared to AD, PD and FTLT, suggesting a potential role as biomarkers¹⁴⁶. However, no significant difference has been observed in any CSF chitinase level between asymptomatic 'at risk' ALS and healthy controls, suggesting that it will likely not have utility in a biotypic biomarker profile¹⁴⁷. Although a single paper has suggested that CSF levels of TREM2 are significantly elevated in early stage levels of ALS over late stage and healthy controls, absent the values of one outlier in the early ALS group, this differentiation is lost¹⁴⁹. The use of proinflammatory molecules as biotypic biomarkers thus, at this moment, has not been demonstrated.

Biomarkers in predicting phenoconversion in ALS

The utility of biomarkers in predicting phenoconversion to clinically manifest ALS has only recently come under study¹⁵⁰. In a prospective longitudinal study of carriers of ALS-associated gene mutations (“at risk” individuals) both serum and CSF pNFL levels have been shown to be elevated within a 12 month window of time prior to the appearance of ALS¹²⁸. Serum and CSF pNFL levels were found to be highly correlated and stable over time apart from those individuals who phenoconverted. In contrast, CSF and serum pNFH levels were poorly correlated. While, serum or CSF NFL levels have been observed to increase prior to phenoconversion, a higher rate of change of serum pNFH over time was observed only among those who phenoconverted¹⁵¹. This latter finding is supported by the observation of elevated serum pNFH levels in a small cohort of pre-diagnostic ALS patients as early as 26 months prior to diagnosis¹⁴³. It is unknown whether this is reflective of the generation of autoantibodies against pNFH or the contribution of pNFH aggregates to either assay variability¹⁵². The measurement of plasma pNFH, at least experimentally, can be confounded by the ‘hook effect’ whereby pNFH aggregates may bind soluble pNFH and give rise to falsely low levels on immunoassays, a challenge that might be obviated by more harsh solubilization¹⁵³.

Although the numbers were small, both Benatar studies suggested an impact of underlying disease genotype^{128,151}. In eight (8) presymptomatic *C9orf72* hexanucleotide expansion carriers, no differences from baseline CSF NFH or NFL levels were observed in a 4 month window prior to disease onset, although statistically significant increases in both were observed coincident with the appearance of clinically overt ALS¹³³. In this context, it is relevant to note that in a longitudinal study of individuals “at risk” for AD (members of families carrying autosomal dominant mutations in *APP*, *PSEN1* or *PSEN2*), while CSF and serum levels of NFL became significantly elevated on average 6.8 years before symptom onset, the rate of change of serum NFL levels became statistically different from controls on average 16.2 years before symptom onset¹⁵⁴. Similar observations of age-adjusted increases in the annual rate of change of serum NFL levels in asymptomatic “at risk” FTD genetic mutation carriers at the time of phenoconversion have been reported, but do not differentiate between pre-symptomatic and post-symptomatic rises¹⁵⁵. These findings strongly suggest that single point measures of either CSF or serum NFL levels will not be of value in detecting phenoconversion beyond establishing baseline levels for an individual and that monitoring the rate of change over time will be equally if not more important.

Biomarkers of FTD/FTLD

The literature surrounding the use of biomarkers to detect FTLD is a complex web of individual studies of FTD alone, comparator studies against AD, disease mimics and

controls, or less frequently, studies to differentiate amongst subsets of FTD. Virtually all focus on the issue of clinical detection or discrimination and are thus generally (mistakenly) viewed as diagnostic biomarkers. With the exception of reduced serum, plasma or CSF progranulin levels in FTD patients harbouring a *GRN* null mutation (FTD-*GRN*), including pre-symptomatic carriers, there is no single specific biomarker of FTD. Rather, as will be discussed, there is a need for a combination of biomarkers with careful attention to the nature of the biosample [e.g., CSF, blood (whole blood, serum, plasma)], to the bioassay methodology employed and, crucially, the clinical population to which they are being applied¹⁵⁶⁻¹⁵⁸.

Plasma biomarkers have proven to be of value in discriminating FTD from AD/MCI (Alzheimer's disease and A[®]-PET-positive mild cognitive impairment), Lewy body dementia, progressive supranuclear palsy (PSP) and nondemented controls¹⁵⁹. Using the Simoa platform, only increased plasma NFL levels discriminated FTD from controls, while increased levels of NFL, GFAP, pThr¹⁸¹ tau and reduced A[®]_{42/40} differentiated AD/MCI from FTD and PSP. These results are consistent with earlier studies showing the utility of plasma pThr¹⁸¹ tau to differentiate AD (elevated) from FTD (not elevated) and controls¹⁶⁰⁻¹⁶², with the specificity enhanced when combined with measures of A[®]₄₂ protein and NFL^{158,163,164}. The use of CSF NFH levels does not add further specificity¹⁶⁵. Further differentiation between FTLD-tau and FTLD-TDP can be achieved using CSF pThr¹⁸¹/t-tau ratios, with a significantly lower ratio in FTLD-TDP than observed in controls and FTLD-tau¹⁶⁶⁻¹⁶⁸ although this level of discrimination has not been observed in all studies¹⁵⁸.

A major advance has been the recent use of the NULISA CNS panel to differentiate amongst AD (including A[®] positive MCI), FTD (including bvFTD, nonfluent variant PPA, semantic variant PPA), PSP and Lewy body disease [including diffuse Lewy body disease (DLB), Parkinson's disease (PD) with dementia], revealing that elevated serum pThr²³¹tau and GFAP levels differentiated MCI, AD, LBD and PSP from healthy controls while elevated pThr²¹⁷ levels differentiated MCI, AD and LBD from healthy controls¹⁶⁹. Serum NFL levels were nonspecifically elevated across all degenerative states¹³⁵. In differentiating PSP and FTD from healthy controls, elevated plasma NFL and reduced corticotrophin releasing hormone (CRH) serum levels were significant. Markers of inflammation assayed using the NULISA inflammation panel were elevated across all disease states compared to controls. These latter observations support the concept that any panel of biotypic biomarkers will need to broadly span neuronal injury, pathologically modified proteins and inflammatory markers.

Few studies have attempted to correlate antemortem CSF tau levels, alone or as part of a suite of bioassays, with postmortem neuropathological findings. Irwin et al¹⁷⁰ examined the

correlation between CSF t-tau, pThr¹⁸¹ tau and A[®]₁₋₄₂ with t-tau (albeit using AT8, a marker for pSer²⁰²/pThr²⁰⁵ tau) cerebral load postmortem in FTLD-tau (n=31), FTLD-TDP (n=49) and AD (n=26). Across all groups, average cerebral tau correlated with CSF pThr¹⁸¹ tau but not t-tau, with a nonsignificant trend towards lower CSF pThr¹⁸¹ tau in FTLD-TDP. In addition, AD co-pathology with FTLD was independently associated with higher pThr¹⁸¹ tau. Excluding this latter group, pure FTLD-TDP patients had significantly lower pThr¹⁸¹ tau than pure FTLD-tau patients. In all instances, lower CSF A[®]₁₋₄₂ levels were associated with AD pathology postmortem as would be expected¹⁷¹. This is consistent with earlier studies demonstrating that a combination of elevated pThr¹⁸¹ tau with low (below control) CSF A[®]₁₋₄₂ levels is specific to AD, while reduced or normal levels of pThr¹⁸¹ in association with reduced A[®]₃₈, A[®]₄₀, A[®]₄₂ or A[®]_{38/42} is specific to FTD¹⁷². Others, however, have observed increased A[®]₄₂ CSF levels to be characteristic of FTD, although with wide variability¹⁵⁸. Despite limited numbers, a trend towards higher CSF NFL levels in neuropathologically confirmed tau negative FTLD (n=7) than in FTLD-tau (n=3) cases has been observed, a trend that is augmented when FTLD with motor neuron degeneration (ALS-FTD) is included amongst the tau-negative (TDP-43) cases^{164,173}. Moreover, CSF pThr¹⁸¹/t-tau ratios have been observed to be lower in neuropathologically confirmed FTLD-TDP than in FTLD-tau¹⁷³. The addition of CSF NFL levels to the National Institute on Aging-Alzheimer's Association ATN framework (CSF A[®]₁₋₄₂, pThr¹⁸¹tau, t-tau) in a neuropathologically confirmed series of AD and FTLD cases significantly increased the ability of the framework to correctly identify those individuals with FTLD (in whom NFL levels were increased)¹⁷⁴. Plasma pThr¹⁸¹ levels differentiate neuropathologically confirmed AD from both FTLD-tau and FTLD-TDP with no difference amongst carriers of *MAPT*, *GRN* or *C9orf72* mutations¹⁷⁵. All of which suggests that differentiating FTLD-tau, FTLD-TDP and AD from healthy controls and each other will be heavily reliant on the combination of NFL, pThr¹⁸¹ (either singly or as a ratio to t-tau) and A[®] fragments.

Used in isolation, NFL levels in serum, plasma or CSF can be helpful in discriminating FTD from cognitively intact controls and psychiatric patients with greater consistency for CSF biosamples^{129,135,176}. The ability to discriminate mild cognitive impairment and disease mimics was less robust. FTD patients as a whole demonstrate a negative correlation between CSF and serum NFL levels on the one hand and brain atrophy as measured by grey matter density or atlas based volumetry on the other hand¹⁷⁷⁻¹⁷⁹.

Biomarkers in association with genetic variants of FTD/FTLD

With respect to the individual genetic variants of FTD, CSF NFL levels have been found to be elevated in FTLD-*C9orf72* and FTLD-*MAPT* variants over FTLD-*GRN*, whereas NFL levels were consistently observed to be significantly elevated in FTLD-*GRN* over the former two

variants^{141,158,180}. In an untargeted proteomics CSF analysis of symptomatic carriers of *C9orf72* pathological hexanucleotide expansion, *GRN* or *MAPT* mutations in whom NFL, NFM, CHI3L1 and NFH expressions were significantly upregulated¹⁸¹.

In modelling disease progression in asymptomatic carriers of these genetic FTD variants, a multimodal approach that included MR imaging allowed for a more nuanced detection of disease¹⁸². Amongst all three FTD genetic variants, while regional brain atrophy and elevated NFL plasma levels were the initial indicators of disease presence, the period of latency from the initial appearance of a biomarker to disease manifestation varied markedly, ranging from 30 years for NFL elevations in *C9orf72* patients to 15 years in *GRN* patients and just prior to clinical manifestations in *MAPT* patients. In contrast to these results, no association between autopsy confirmed *C9orf72* pathological expansion and any biomarker was observed in a recent study, although potentially confounded by a small sample size (n=8)¹⁸³. The role of plasma NFL levels in predicting phenoconversion amongst *C9orf72* expansion carriers is less clear¹⁴¹.

Predicting phenoconversion in FTD/FTLD

There is limited data with respect to the use of biomarkers to predict phenoconversion in FTD/FTLD. Age-adjusted increases in the rate of change of serum or plasma NFL levels have been shown to occur coincident with phenoconversion in genetically “at risk” FTD^{135,141,155,180}. Rojas et al¹⁸⁰ examined the role of plasma NFL levels (Simoa platform) in distinguishing ‘at risk’ individuals (*C9orf72*, *GRN*, *MAPT* mutation carriers) from family members without genetic risk across asymptomatic, prodromal and full phenotype, including both an original cohort and a replication cohort with a multimodal approach that included disease severity and neuropsychological scales, CSF biomarkers (NFL, neurogranin) and brain MRI. Consistent with earlier reports, symptomatic mutation carriers exhibited significantly higher plasma NFL levels with excellent correlation to CSF NFL levels, while for those patients asymptomatic at baseline who subsequently phenoconverted, median baseline NFL concentrations were higher in both the original and validation cohorts. The latter group also exhibited lower frontal and temporal brain volumes after 2 years with neuropsychological decline. Finally, while CSF levels of soluble TREM2 are significantly elevated in both symptomatic and asymptomatic *GRN* mutation carriers, its value in a potential suite of biotypic biomarkers directed at predicting phenoconversion is not yet clear¹⁸⁴.

Biomarkers of ALS concomitantly with FTD/FTLD

All the challenges described above become amplified when both clinical syndromes are present. In a comparison of FTLD-TDP with or without ALS to FTLD-tau, AD and a control

group with subjective memory complaints, while CSF NFL levels were increased across all neurodegenerative states, the greatest were amongst those with FTLD-TDP and ALS followed by FTLD-TDP without ALS versus all others, suggesting that the presence of concomitant ALS was a significant driver of elevated NFL levels¹⁶⁸. This finding is consistent with subsequent observations, including in neuropathologically confirmed FTLD with or without ALS^{174,180}. It is also consistent with elevated CSF and plasma NFL levels observed when compared to a cohort of patients with primary psychiatric disorders, suggesting utility as a diagnostic biomarker in differentiating the latter from the former¹⁸⁵. Elevated plasma GFAP/NFL ratios have been shown to correlate with pathologically-confirmed tau burden and to discriminate between sporadic FTLD-tau and FTLD-TDP, such that it is elevated in the former although levels in both were observed to be less than healthy controls¹⁸⁶. None of these measures, however, speak to the existence of biotypic biomarkers sensitive to the underlying pathophysiology of ALS-FTSD.

In summary, there is very little in the literature regarding biotypic biomarkers in FTD, in part related to the heterogeneous nature of the disorder and in part due to the understandable focus and the development of diagnostic biomarkers. However, such a broad view does yield a number of specific consistencies that will be of assistance in informing the development of a biotypic biomarker panel:

(i) Reduced CSF and plasma progranulin levels are specific to FTLD-GRN.

(ii) In general, while there is significant variability across studies, FTD/FTLD can be differentiated from AD and controls using a panel of biomarkers. These include NFL (which, although lacking specificity when used in isolation, is most consistently elevated in CSF and blood, serum or plasma when compared to cognitively intact controls), pThr¹⁸¹tau (most consistently reduced in comparison to controls and AD) and measures of A β protein that can include A β ₃₈, A β ₄₂, A β _{38/42} or A β _{42/40} (consistently elevated in CSF from FTD/FTLD and decreased in AD).

(iii) Lower CSF pThr¹⁸¹/t-tau ratios with increased NFL levels may differentiate FTLD-TDP from FTLD-tau (increased t-tau and pThr¹⁸¹ with increased pThr¹⁸¹/Ab₄₂ ratio and no change in NFL)¹⁸³ although this finding warrants further study.

(iv) The technology underlying the Simoa and NULISA platforms represents a significant advance in the ability to detect trace levels of biomarkers at femtomolar concentrations with both showing good correlations for key CNS proteins measured in plasma and serum¹⁶⁹. However, both are still reliant on an antibody:antigen interaction, albeit at single molecule levels, so issues of antigenic specificity, the nature of protein fragments being detected, and the collection conditions remain present. Addressing these issues will remain paramount as untargeted omics approaches within validation workflows in the identification of novel biomarkers.

Future research directions

Cryptic peptides as biotypic biomarkers of nuclear TDP-43 depletion

The discovery that CE-containing transcripts or the resulting cryptic peptides (CP) can serve as specific CSF or blood biomarkers of nuclear TDP-43 depletion represents a significant advance in our understanding of ALS, ALS-FTD, FTLD-TDP and LATE-NC^{33-39,42,187,188}. The presence of specific cryptic exons/peptides (e.g., STMN2, UNC13A, and HDGFL2) is highly specific to TDP-43 proteinopathies and generally absent in healthy controls or other neurodegenerative diseases like FTLD-tau. In postmortem tissue, there is a high degree of concordance between HDGFL2-CE protein (in contrast to the wild-type protein: HDGFL2-wt) and pTDP-43 burden in ALS-FTD, FTLD-TDP and AD-TDP⁴⁰.

In a comprehensive study of brains from individuals aged 21 – 109 years, Chang and colleagues⁴² observed that TDP-43 nuclear clearance accompanied by HDGFL2-CE protein expression precedes the appearance of TDP-43 neuronal cytoplasmic inclusions by a decade, suggesting that HDGFL2-CE protein expression may be a viable biotypic marker of a presymptomatic TDP-43 proteinopathy. Using a proteomics approach, Seddighi and colleagues³⁹ observed the expression of six CPs, including HDGFL2, in CSF of ALS-FTD patients. Supporting the potential role for CPs in presymptomatic testing, elevated levels of cryptic HDGFL2 in both CSF and plasma have been reported in pre-symptomatic ALS and ALS-FTD carriers of pathological C9orf72 hexanucleotide expansions, though conclusions should be tempered by poor assay sensitivity³⁸. Although the numbers studied were small, longitudinal data were very limited, and a validation study is clearly needed, these authors hypothesize that elevations in CSF cryptic HDGFL2 would precede the elevations in NFL or pNFH in predicting phenoconversion.

Extracellular vesicles (with relevance to pTDP-43, tau and miRNAs)

Extracellular vesicles (EVs), while challenging to isolate, are increasingly being studied as tools in the quest for biotypic biomarkers given their core role in both physiological and pathological intercellular communication by transporting proteins, nucleic acids and lipids between cells, including those associated with pathological aggregate formation¹⁸⁹⁻²⁰⁰.

Relevant to this discussion, both tau and TDP-43 can undergo cell-to-cell transfer via EVs and are capable of recruiting endogenous proteins into existing aggregates^{104,201-204}. Recent studies have provided evidence for relevant differences in biophysical properties of EVs between ALS and healthy controls, including their cargos [ie., pTDP-43, tau isoforms (3R, 4R), HSP90 or cyclophilin A (PPIA)]^{203,205,206}. While these measures remain to be further explored and validated, their specificity and direct biological relevance make EVs an attractive biosample.

An example of a potential role for EVs is in the quantification of neural-specific microRNA (miRNA) expression. These endogenous small non-coding RNAs have unique expression profiles depending on the cell or tissue of origin and are crucial regulators of gene expression by interacting directly with mRNA 3'UTRs to drive, in the majority, but not always, degradation of the mRNA transcript²⁰⁷⁻²⁰⁹. The challenge using miRNAs as a biomarker has been the marked variability in defining specific miRNAs, either individually or in clusters, based on the tissue specificity, stage of disease or the failure to adequately define the efficiency of the EV isolation methodology. The use of standardized methodologies to isolate and evaluate EVs from CSF or blood may help resolve this issue²¹⁰⁻²¹⁵. Suggesting that such studies have potential in the development of a biotypic biomarker profile, significant alterations in a panel of 24 miRNAs have been identified as downregulated in fALS patients (*mtSOD1*, *mtFUS*, *C9orf72* hexanucleotide expansions) versus healthy controls as early as two decades prior to symptom onset²¹⁶. Whether the up-regulation of miR-206 and miR-151a-5p observed in “mild” stages of ALS are reflective of phenoconversion remains to be seen²¹⁷.

Telomeric length as a marker of biological aging

Telomeres are repeat sequences of TTAGGG in association with the protein complex shelterin that cap the ends of chromosomes and serve to maintain DNA integrity by preventing the loss of gene sequences²¹⁸. Because telomeric DNA cannot be completely replicated by DNA polymerases, telomeres are gradually shortened with each replication cycle until a critical point is reached at which genomic instability occurs that in turn leads to senescence and cell death. Although telomerases add nucleotides to telomeres, serving to maintain telomere length, somatic cells generally have low levels of telomeric activity resulting in progressive shortening over time²¹⁹. Telomere shortening, or attrition, is thus thought to be a marker of aging^{220,221}. In the context of women tending to have longer telomeres than men, it is interesting that the lifetime risk for ALS is higher for men and that male:female ratios for ALS change significantly during aging²²²⁻²²⁶.

Although there is no association between telomere length and the risk of developing ALS, perhaps counter-intuitively telomere length in ALS has been observed to be significantly longer than in age and sex-matched controls with those individuals amongst the ALS cohort with shorter telomere length tending to have a longer median survival²²⁶⁻²²⁸. This lengthening has been proposed to be due to the rate of attrition being slower as opposed to active lengthening by telomerases²²⁶. Of interest, longer telomeres have also been associated with FTD, including ALS-FTD, although the numbers studied were small and not replicated across all studies²²⁹⁻²³¹. It remains to be determined whether, as a component of

a multimodality tool, age- and sex-adjusted telomeric measurement as an index of resiliency might be a valuable addition to a biotypic biomarker profile.

Epigenetic markers of biological risk

Epigenetics refers specifically to those alterations in gene expression that occur independently of alterations in the DNA sequence and are largely held to reflect changes in DNA methylation, histone posttranslational modifications, chromatin remodelling and modifications of the interactions of RNA with DNA, ultimately affecting gene transcription²³²⁻²³⁴. The majority of DNA methylation, regulated by DNA methyltransferases, occurs at carbon-5 of the pyrimidine ring of cytosine (5-mC) when followed by a guanine repeat (CpG dinucleotide), resulting in inhibition of gene transcription when adjacent to promoter regions^{235,236}. CpG islands, regions of greater than 500 basepairs with high CpG content often clustered in promoter regions and typically hypomethylated, are hypermethylated with age leading to transcriptional silencing²³⁵.

DNA methylation is increased in genomic DNA extracted from the blood of ALS patients with *SOD1* mutations and in brain DNA derived from the frontal cortex of sALS patients^{237,238}. In the former, DNA methylation levels in presymptomatic carriers were similar to control, raising the question as to the exact timing of alterations in DNA methylation status in the context of phenoconversion. It is noteworthy that increased CpG island methylation near the promoter region of *C9orf72* has been observed in *C9orf72* ALS, ALS-FTD and FTD, predominantly in large repeat expansions ($(G_4C_2)_n$ ($n > 90$)) with reductions in promoter activity and moreover, that the $(G_4C_2)_n$ methylation was evident in both blood and brain samples, including asymptomatic carriers²³⁹⁻²⁴¹. Emerging work suggests that epigenetic profiling of cell-free DNA (cfDNA) may offer a minimally invasive route to brain-derived biomarkers. Tissue-of-origin-specific DNA methylation patterns in cfDNA have been used to infer the presence of neurodegenerative diseases including ALS and FTD, by identifying neuron subtype specific DNA methylation signatures²⁴²⁻²⁴⁴.

Epigenetic drift, referring to age-related changes in the patterns of DNA methylation (either hypo- or hypermethylation) has been observed in symptomatic ALS cases when compared to neurologically intact controls²⁴⁵. DNA methylation can also be used to provide a biological age estimate (DNAm age), sometimes termed the “epigenetic clock” in which cumulative methylation levels across 353 CpGs measured using a genome-wide array [of which, using the “clock” developed by Horvath²⁴⁶, 193 CpGs increase methylation levels with age while 160 decrease]²⁴⁶. While acceleration of DNAm age has been linked to earlier disease onset and shorter survival in both sporadic and *C9orf72* ALS^{241,247,248}, its potential role as a modifier with a biotypic biomarker profile has yet to be addressed.

Beyond DNA methylation signatures of disease and biological ageing, other epigenetic mechanisms, particularly histone modifications, represent a promising but underexplored avenue for ALS and FTD biomarker discovery. Studies in AD and PD have shown that disease-associated alterations in histone acetylation and methylation can be detected in both brain tissue and peripheral cells and may track with pathological burden and clinical progression²⁴⁹⁻²⁵². Translating similar approaches to ALS and FTD could help identify histone-based signatures that reflect disease processes such as early neuronal dysfunction, synaptic disturbance, or neuroinflammation²⁵³. More broadly, epigenetic marks across multiple layers may encode the cumulative imprint of environmental and lifestyle exposures (e.g. smoking, metabolic factors, toxins, physical activity) on disease-relevant pathways²⁵⁴⁻²⁵⁶.

Polygenic Risk Score (PRS)

The awareness that neurodegeneration occurs on the background of a genetic risk profile in which the absence of specific genetic risk variants or the presence of genetic variants associated with healthy cognitive aging or enhanced longevity, respectively, is fundamental to any discussion of a biotypic biomarker profile²⁵⁷. This concept has been central to the construct of a polygenic risk score (PRS) from large genome-wide association studies (GWAS) evaluating single nucleotide polymorphisms (SNPs) as a methodology to aggregate genetic markers that do not individually reach significance^{258,259}. For example, when applied to cognitively healthy centenarians, a number of novel protective alleles were identified (*ANKH*, *GRN*, *TMEM106B*, *SORT1*, *PLCG2*, *RIN3*) in addition to APOE genotype that could be attributed to reducing AD risk by greater than 5 fold.²⁶⁰ When used in combination with age, sex and the expression of the APOE- ϵ 4 allele, a PRS [also termed a genetic risk score (GRS)] constructed from the European Alzheimer & Dementia Biobank with 83 genome-wide significant variants predicted conversion to AD in population-based studies and from MCI to AD in MCI cohorts, with the risk for both cohorts rising with an increased number of risk alleles independent of non-APOE risk variants²⁶¹.

In FTD, the *rs1990622*^G allele of *TMEM106B* shows both protective effects on age at phenoconversion, as well as effects on several of the biomarkers discussed above²⁶²⁻²⁶⁴. In *GRN* carriers and *C9orf72* carriers, the *rs1990622*^G allele is associated with reduced atrophy, lower NFL levels, and/or better cognitive performance²⁶⁵. Many of these differences are observed at baseline assessments even in presymptomatic carriers, highlighting the potential impact at the neurodevelopmental level a complex interplay between risk and protective factors across the lifespan which will influence models of phenoconversion prediction.

A similar approach using single variant GWAS to identify novel risk genes and foci specific to FTLD-TDP pathological subtypes identified a genome-wide significant signal at the *UNC13A* locus for all FTLD-TDP variants²⁶⁶. The most significant locus for FTLD-TDP type was *GRN* in addition to several new significant loci (*TINAG*, *MZT1*, *FARP2*). The most significant association with FTLD-TDP type B was for the *UNC13A* locus, with three new risk loci (*TNIP1*, *RCL1* and *PDS5B*). For neuropathologically-confirmed FTLD-TDP type C, four genome-wide significant loci were identified, including *LRP1B*, *COL22A1*, *TMEM135* and *TRPC4* [having excluded semantic variant Primary Progressive Aphasia (svPPA)]. When the expression of these subtype specific gene expression profiles was compared to published loci for Alzheimer's disease and related disorders (ADRD) and to an ALS GWAS, FTLD-TDP subtypes presented a distinct genetic signature with the exception of *UNC13A* colocalization with ALS and *TNIP1* with both ALS and ADRD. For the first time, this provides a window of opportunity to consider a biotypic biomarker profile with specificity to individual FTLD-TDP subtypes antemortem.

Although few studies have examined the role of PRS in ALS, an increase in PRS over controls is associated with an increased risk of ALS and moreso for those individuals without rare ALS-causative variants^{267,268}. While the risk contribution to those harbouring ALS-associated rare variants appeared nonsignificant, sample size was limited. These findings were consistent with prior observations that genome-wide significant loci could account for only 0.2% of heritability in ALS²⁶⁹. Of note, a higher PRS for cognitive impairment in ALS was associated with both neuroimaging evidence of cortical thinning and neuropathological features (neuronal loss, TDP-43 pathological inclusions) in domains known to be associated with cognitive dysfunction²⁷⁰. Several of the SNPs were shared risk loci for FTD (in or near *MOBP*, *NSF*, *ATXN3*, *ERGIC1* and *UNC13A*). Although no inference from these studies can be made with respect to predicting those individuals at risk for phenoconversion, future studies will need to consider a broader range of genetic risk profiles in both ALS and FTD, including both monogenic and oligogenic inheritance in addition to PRS profiles^{271,272}.

Conclusions

The challenge in utilizing existing biomarkers to predict phenotypic conversion is that the majority of biomarkers to date are linked to clinical phenotype, not as biotypic biomarkers linked to the underlying biology. However if existent biomarkers are viewed in the context of their ability to detect the process of neurodegeneration, even while being agnostic to the exact nature of the disease itself (i.e., biotypic biomarkers), then this may well be sufficient if the goal is to identify 'at risk' individuals who have entered into a phase of subclinical

biological activity (Figure 4). In this conceptualization, evolving biomarkers such as those linked to alterations in lipid metabolism²⁷³⁻²⁷⁶ or the previously discussed genetic markers (telomeric length, epigenetic modifications and PRS) might be considered most appropriately as susceptibility or risk biomarkers. Amongst all of the biomarkers currently available, the use of CSF, blood or plasma levels of NFL appears to be the most sensitive to the presence of such an underlying neurodegenerative process although it lacks disease specificity^{171,277}. If one is simply wishing to detect the presence of prodromal disease and in doing so sacrifice specificity, then NFL would seem to be the current leader^{177,277}.

If however the goal is to identify biotypic biomarkers that reflect the underlying proteinopathy and then determine whether these biomarkers predict divergent phenotypes of clinical disease, then no single biomarker has sufficient specificity and sensitivity to be considered a “gold standard” for the characterization or definition of an individual neurodegenerative disease process. The cumulative weight of the literature suggests that a multimodal biotypic biomarker profile will be required, not only in the prediction of phenoconversion, but in the identification of the underlying pathobiology irrespective of the conversion. Such a profile is likely to be influenced by issues of genetic tolerance and susceptibility. Although not discussed in detail in this review, such a biotypic biomarker profile will necessitate the integration of clinical data, neuroimaging and biophysical studies²⁷⁸⁻²⁸². Given these considerations, as biotypic biomarker profiles are developed and replicated, a number of key issues need to be considered.

First and foremost, there is a limited availability of large cohorts of deeply endophenotyped presymptomatic individuals who have been followed longitudinally over time using an array of both biochemical biomarkers (as reviewed in this article) with detailed clinical markers as referenced in the preceding paragraph. As reviewed by Benatar et al²⁸³, such priority studies are challenging on multiple fronts, including ensuring clear operational definitions of disease stage, ethical considerations, and ultimately, cost. Moreover, as the evidence in support of biomarkers reflective of involvement of the peripheral nervous system and muscle evolve, such biomarkers will need to be evaluated as potential sensitive indicators of early metabolic remodelling and inflammatory signalling in distinguishing ALS from FTD phenotypes.

Secondly, if the concept of a multimodal biotypic biomarker profile is to have utility, its individual constituents should have relevance to the underlying pathobiological processes. Ideally, such a profile should be developed with age- and sex-adjusted normative data used to establish appropriate cut-off values. For individual proteins that are known to undergo extensive PTMs, efforts should be made to ensure that disease-specific epitopes are addressed. A case in point is the need to more clearly define the tau fragment(s) on which

t-tau assays are reported and in accurately characterizing disease-specific CSF fragments of NFL. Doing so will provide unique protein or peptide signatures beyond simply reflecting nonspecific features of axonal degeneration^{138,284}. The same can be said for TDP-43 although the advent of cryptic peptides as a biotypic biomarker may mitigate this need. Once extracted, the candidate biomarkers should be biologically stable during storage or, at minimum, the impact of storage over prolonged periods of time corrected for.

There should be a significant correlation between CSF and blood, serum or plasma values for any given biotypic biomarker included in the profile that is thought to reflect pathophysiological processes arising within the central nervous system. For biosamples arising from outside of the CNS (e.g., skin, gut or muscle), this might not apply although a greater understanding of the correlation with CNS pathobiological processes will be crucial.

While the bulk of attention of this review has been on identifying biotypic biomarkers capable of predicting phenoconversion in ‘at risk’ individuals, the challenge of predicting those individuals whose existent clinical disease state will evolve from a “pure” ALS or FTD phenotype into an ALS-FTSD also exists. Further research with a focus on cohorts investigating these questions are necessary to solve this.

Acknowledgements

The authors would like to acknowledge the critical and timely comments of the manuscript by Dr Michael Benatar.

Funding

The research workshop was made possible through generous unrestricted educational grants from the ALS Society of (Windsor) Essex County (lead sponsor & sponsorship of junior faculty members), the Temerty Family Foundation, Biogen Canada, The ALS Society of Canada, Alector, Eli Lilly and Company, the Motor Neurone Disease Association, Mistubishi Tanabe Pharma (Canada).

Competing interests

A.A. reports consultancies or advisory boards for Amylyx, Apellis, Biogen, Clene Therapeutics, Cytokinetics, GenieUs, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Qoralis, Sano, Sanofi, Vesalic, Voyager Therapeutics, and Wave Pharmaceuticals, and the following patents under consideration or approved: Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients WO2024121173A1; IL-2 for the treatment of frontotemporal dementia disorder EP25306172.5. B.B. has served as an investigator for clinical trials sponsored by Alector, Cognition Therapeutics, EIP Pharma/Cervomed, and Transposon. He serves on the Scientific Advisory Board of the Tau Consortium, which is funded by the Rainwater Charitable Foundation. He receives research support from the NIH, Lewy Body Dementia Association, American Brain Foundation, Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, Little Family Foundation, and Ted Turner and Family Foundation. E.F. reports advisory fees from Takeda/Denali, Vigil Therapeutics Inc., Ionis and Biogen, and research support from CIHR and the Weston Foundation. H.H. reports support by ABOARD, a public-private partnership receiving funding from ZonMw (73305095007) and Health Holland, Topsector Life Sciences & Health (LSHM20106), the Hans und Ilse Breuer Stiftung (2020), the HorstingStuit Foundation (2018), and the Dutch Research Council (Aspasia premie 015.016.059). E.L. reports consulting fees from Eli Lilly. M.S. reports research support from the Canadian Institutes of Health Research (CIHR grant SOP-160442) and the Temerty Family Foundation. MJS is a member of the Scientific Advisory Board of the Saudi Arabia National Institutes of Health M.O. received research support from the German Federal Ministry of Education and Research (projects: FTLDc 01GI1007A), the EU: Moodmarker, PredictFTD, Synapsing, the ALS Association, the foundation of the state Baden-Württemberg, Boehringer Ingelheim Ulm University BioCenter, and the Thierry Latran Foundation and EU-MIRIAD, EU-PredictFTD, Synapsing, Moodmarker and the Roux-programme of the Martin Luther University Halle (Saale); MO. received consulting fees from Biogen, Axon, Roche, and Grifols; and participates on the Biogen ATLAS trial board, all unrelated to the work presented in this paper; is a speaker of the German FTLD consortium, is involved in an unpaid role with the German Society for CSF Diagnostics and Neurochemistry, and is involved without pay with the Society for CSF Diagnostics and Neurochemistry. L.P. is a consultant for Expansion Therapeutics. L.P. is supported by the National Institutes of Health (R01NS120992, U54NS123743, R35NS097273), the Target ALS Foundation. M.P. reports no conflicts. M.P. is supported by the National Institutes of Health (R01NS120992, U54NS123743), the Target ALS Foundation (#9), the BrightFocus Foundation (A2024017S), and the Kissick Family Foundation (MILKEN#5). T.S. has served as a consultant for Blue Rock Therapeutics, Centessa, Critical Path for Parkinson's

Consortium (CPP), MJFF, Prevail/Lilly Roche/Genentech, Ventus, Sinopia, Takeda, Vanqua Bio, Ventus, Ventyx, and VIMA Tx. Dr. Simuni has equity in Sinopia and has served on the advisory board for AskBio, Biohaven, Booster, GAIN, Janssen, Neuron23, Novartis, Parkinson Study Group, Prevail/Lilly, and Roche/Genentech. Dr. Simuni has served as a member of the scientific advisory board of Koneksa and UCB. Dr. Simuni has received research funding from Neuroderm, Prevail, Roche, NINDS, MJFF, and Parkinson's Foundation. C.T. reports participation in advisory boards for Eisai, Lilly, Roche, Novartis and Novo Nordisk. MCT is supported by Weston Family Foundation, Brain Canada, Michael J Fox Foundation, Tannenbaum Institute for Science in Sport, Workplace Safety and Insurance Board. MCT is on Scientific Advisory Board of the Association for Frontotemporal Degeneration. P. Van Damme reports participation in advisory boards for Biogen, CSL Behring, Alexion Pharmaceuticals, Ferrer, QuraAlis, Cytokinetics, Argenx, UCB, Muna Therapeutics, Alektor, Augustine Therapeutics, VectorY, Zambon, Amylyx, Novartis, Prilenia, Verge Genomics, Sapreme Technologies, Trace Neuroscience, NRG Therapeutics (paid to institution). PVD has received speaker fees from Biogen and Amylyx (paid to institution). PVD is supported by the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders (paid to institution). D.W. served as a consultant for Beckman Coulter, on the DSMB for GSK, and was site-PI for a study by Biogen for which his institution received grant funds. All other authors report no competing interests.

Supplementary material

Supplementary material is available at *Brain* online.

Appendix 1

Workshop attendees

Samir Abu Rumeileh, Ammar Al-Chalabi, Sharon Abrahams, Megan Barker, Michael Benatar, Alberto Benussi, Bradley Boeve, Robert Bowser, Idnu Navar Bingham, Danae Campos-Melo, Sharon Coleman, Johnathon Cooper-Knock, Kathryn Cousins, Joke De Vocht, Cristian Droppelmann, Elizabeth Finger, Leah Forsberg, Nicole Harris, Lee Freiburger, Jenna Gregory, Henne Holstege, Edward Huey, Clifford R. Jack, Jr. Murray Junop, Sanjay Kalra, Brianna Kaplanis, Raffaella Klima, Edward Lee, David Lester, Irene Litvan, Alessandra Longo, Sarah Marzi, Caroline McHutchison, Crystal McLellan, Roison

McMackin, Corey McMillan, Christopher M Morrow, Veronica Noches, Panteleimon Oikonomou, Nicholas Olney, Bjorn Oskarsson, Chiadi U. Onyike, Markus Otto, Frederica Palacino, Francesca Paron, Dung Pham, Yolande Pijnenburg, Barbara Poletti, Kathleen Poston, Mercedes Prudencio, Janice Robertson, Angela Roberts, Alex Salazar, Niyatee Samudra, Christen Shoesmith, Vincenzo Silani, Isis So, Tomas Solomon, Michael Strong, Carmella Tartaglia, David Taylor, Martin Turner, Michael Van Es, Juan-Camilo Vargus-Gonzalez, David A. Wolk.

For further details, see the Supplementary material.

References

1. Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotroph Lateral Scler Frontotemporal Degener.* 5/2017 2017;18(3-4):153–174. doi:10.1080/21678421.2016.1267768 [doi]
2. Tamminga CA, Clementz BA, Pearlson G, et al. Biotyping in psychosis: using multiple computational approaches with one data set. *Neuropsychopharmacology.* Jan 2021;46(1):143–155. doi:10.1038/s41386-020-00849-8
3. Parker DA, Trotti RL, McDowell JE, et al. Differentiating biomarker features and familial characteristics of B-SNIP psychosis Biotypes. *Transl Psychiatry.* Aug 14 2025;15(1):281. doi:10.1038/s41398-025-03501-5
4. FDA-NIH Biomarker Working Group. *BEST (Biomarkers, EndpointS, and other Tools) Resource.* [Internet] Food and Drug Administration (US); 2016.
5. Oeckl P, Mayer B, Bateman RJ, et al. Early increase of the synaptic blood marker beta-synuclein in asymptomatic autosomal dominant Alzheimer's disease. *Alzheimers Dement.* Apr 2025;21(4):e70146. doi:10.1002/alz.70146
6. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *The Lancet.* 2024;404(10452):572–628. doi:10.1016/S0140-6736(24)01296-0

- 1 7. Irwin KE, Sheth U, Wong PC, Gendron TF. Fluid biomarkers for amyotrophic lateral
2 sclerosis: a review. *Mol Neurodegener.* Jan 24 2024;19(1):9. doi:10.1186/s13024-023-00685-6
- 3 8. de Boer EMJ, Orie VK, Williams T, et al. TDP-43 proteinopathies: a new wave of
4 neurodegenerative diseases. *J Neurol Neurosurg Psychiatry.* Nov 11 2020;92(1):86–95.
5 doi:10.1136/jnnp-2020-322983
- 6 9. Lopez-Carbonero JI, Garcia-Toledo I, Fernandez-Hernandez L, et al. In vivo diagnosis of
7 TDP-43 proteinopathies: in search of biomarkers of clinical use. *Transl Neurodegener.* Jun 3
8 2024;13(1):29. doi:10.1186/s40035-024-00419-8
- 9 10. Luthi-Carter R, Cappelli S, Le Roux-Bourdieu M, et al. Location and function of TDP-43
10 in platelets, alterations in neurodegenerative diseases and arising considerations for current plasma
11 biobank protocols. *Sci Rep.* Sep 18 2024;14(1):21837. doi:10.1038/s41598-024-70822-8
- 12 11. Abu-Rumeileh S, Scholle L, Mensch A, et al. Phosphorylated tau 181 and 217 are elevated
13 in serum and muscle of patients with amyotrophic lateral sclerosis. *Nat Commun.* Mar 5
14 2025;16(1):2019. doi:10.1038/s41467-025-57144-7
- 15 12. Tziortzouda P, Van Den Bosch L, Hirth F. Triad of TDP43 control in neurodegeneration:
16 autoregulation, localization and aggregation. *Nat Rev Neurosci.* Apr 2021;22(4):197–208.
17 doi:10.1038/s41583-021-00431-1
- 18 13. Dang M, Wu L, Zhang X. Structural insights and milestones in TDP-43 research: A
19 comprehensive review of its pathological and therapeutic advances. *Int J Biol Macromol.* May
20 2025;306(Pt 3):141677. doi:10.1016/j.ijbiomac.2025.141677
- 21 14. Cordts I, Wachinger A, Scialo C, et al. TDP-43 Proteinopathy Specific Biomarker
22 Development. *Cells.* Feb 12 2023;12(4)doi:10.3390/cells12040597
- 23 15. Moisse K, Volkening K, Leystra-Lantz C, Welch I, Hill T, Strong MJ. Divergent patterns
24 of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for
25 TDP-43 in the physiological response to neuronal injury. *Brain Res.* Jan 16 2009;1249:202–11.
26 doi:10.1016/j.brainres.2008.10.021
- 27 16. Moisse K, Mephram J, Volkening K, Welch I, Hill T, Strong MJ. Cytosolic TDP-43
28 expression following axotomy is associated with caspase 3 activation in NFL mice: Support for a

- role for TDP-43 in the physiological response to neuronal injury. *Brain Research*. Oct 16 2009;1296:176–186. . doi:10.1016/j.brainres.2009.07.023
17. Strong MJ, Volkening K, Hammond R, et al. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. *Mol Cell Neurosci*. 2007 2007;35(2):320–327. In File.
18. Fakim H, Vande Velde C. The implications of physiological biomolecular condensates in amyotrophic lateral sclerosis. *Semin Cell Dev Biol*. Mar 15 2024;156:176–189. doi:10.1016/j.semcdb.2023.05.006
19. Rummens J, Khalil B, Yildirim G, et al. TDP-43 seeding induces cytoplasmic aggregation heterogeneity and nuclear loss of function of TDP-43. *Neuron*. Mar 26 2025;doi:10.1016/j.neuron.2025.03.004
20. Bodansky A, Kim JM, Tempest L, Velagapudi A, Libby R, Ravits J. TDP-43 and ubiquitinated cytoplasmic aggregates in sporadic ALS are low frequency and widely distributed in the lower motor neuron columns independent of disease spread. *Amyotroph Lateral Scler*. May 3 2010;11(3):321–7. doi:10.3109/17482961003602363
21. Keller BA, Volkening K, Droppelmann CA, Ang LC, Rademakers R, Strong MJ. Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism. *Acta Neuropathol*. 9/1/2012 2012;124(5):733–747. . doi:10.1007/s00401-012-1035-z [doi]
22. Zhang YJ, Xu YF, Cook C, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. *Proc Natl Acad Sci U S A*. 5/5/2009 2009;106(18):7607–7612. . doi:0900688106
23. Schmidt HB, Rohatgi R. In Vivo Formation of Vacuolated Multi-phase Compartments Lacking Membranes. *Cell Rep*. Aug 2 2016;16(5):1228–1236. doi:10.1016/j.celrep.2016.06.088
24. Harrison AF, Shorter J. RNA-binding proteins with prion-like domains in health and disease. *Biochem J*. Apr 7 2017;474(8):1417–1438. doi:10.1042/BCJ20160499
25. Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. *J Biol Chem*. 7/24/2009 2009;284(30):20329–20339. . doi:M109.010264

- 1 26. Conicella AE, Zerze GH, Mittal J, Fawzi NL. ALS Mutations Disrupt Phase Separation
2 Mediated by alpha-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain.
3 *Structure*. Sep 6 2016;24(9):1537–49. doi:10.1016/j.str.2016.07.007
- 4 27. Gopal PP, Nirschl JJ, Klinman E, Holzbaur EL. Amyotrophic lateral sclerosis-linked
5 mutations increase the viscosity of liquid-like TDP-43 RNP granules in neurons. *Proc Natl Acad*
6 *Sci U S A*. Mar 21 2017;114(12):E2466–E2475. doi:10.1073/pnas.1614462114
- 7 28. Grese ZR, Bastos AC, Mamede LD, French RL, Miller TM, Ayala YM. Specific RNA
8 interactions promote TDP-43 multivalent phase separation and maintain liquid properties. *EMBO*
9 *Rep*. Dec 6 2021;22(12):e53632. doi:10.15252/embr.202153632
- 10 29. Vishal SS, Wijegunawardana D, Salaikumaran MR, Gopal PP. Sequence Determinants of
11 TDP-43 Ribonucleoprotein Condensate Formation and Axonal Transport in Neurons. *Front Cell*
12 *Dev Biol*. 2022;10:876893. doi:10.3389/fcell.2022.876893
- 13 30. Ke YD, van Hummel A, Stevens CH, et al. Short-term suppression of A315T mutant
14 human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse
15 model of FTLTDP and ALS. *Acta Neuropathol*. Nov 2015;130(5):661–78. doi:10.1007/s00401-
16 015-1486-0
- 17 31. Wu Y, Wang J, Zhao Q. Advancements in TDP-43 research: Towards biomarkers and
18 therapeutic targets for amyotrophic lateral sclerosis. *Aging and Health Research*. 2025/03/01/
19 2025;5(1):100215. doi:10.1016/j.ahr.2024.100215
- 20 32. Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved
21 cryptic exons is compromised in ALS-FTD. *Science*. Aug 7 2015;349(6248):650–5.
22 doi:10.1126/science.aab0983
- 23 33. Klim JR, Williams LA, Limone F, et al. ALS-implicated protein TDP-43 sustains levels of
24 STMN2, a mediator of motor neuron growth and repair. *Nat Neurosci*. Feb 2019;22(2):167–179.
25 doi:10.1038/s41593-018-0300-4
- 26 34. Melamed Z, Lopez-Erauskin J, Baughn MW, et al. Premature polyadenylation-mediated
27 loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. *Nat Neurosci*. Feb
28 2019;22(2):180–190. doi:10.1038/s41593-018-0293-z

35. Prudencio M, Humphrey J, Pickles S, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. *J Clin Invest.* Nov 2 2020;130(11):6080–6092. doi:10.1172/JCI139741
36. Ma XR, Prudencio M, Koike Y, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. *Nature.* Mar 2022;603(7899):124–130. doi:10.1038/s41586-022-04424-7
37. Brown AL, Wilkins OG, Keuss MJ, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. *Nature.* Mar 2022;603(7899):131–137. doi:10.1038/s41586-022-04436-3
38. Irwin KE, Jasin P, Braunstein KE, et al. A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD. *Nat Med.* Feb 2024;30(2):382–393. doi:10.1038/s41591-023-02788-5
39. Seddighi S, Qi YA, Brown AL, et al. Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD. *Sci Transl Med.* Feb 14 2024;16(734):eadg7162. doi:10.1126/scitranslmed.adg7162
40. Calliari A, Daugherty LM, Albagli EA, et al. HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases. *Mol Neurodegener.* Mar 27 2024;19(1):29. doi:10.1186/s13024-024-00718-8
41. Wolk DA, Nelson PT, Apostolova L, et al. Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy. *Alzheimers Dement.* Jan 2025;21(1):e14202. doi:10.1002/alz.14202
42. Chang K, Ling JP, Redding-Ochoa J, et al. Loss of TDP-43 splicing repression occurs early in the aging population and is associated with Alzheimer's disease neuropathologic changes and cognitive decline. *Acta Neuropathol.* Dec 22 2023;147(1):4. doi:10.1007/s00401-023-02653-2
43. Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. *Brain.* Jun 1 2019;142(6):1503–1527. doi:10.1093/brain/awz099
44. Nelson PT, Lee EB, Cykowski MD, et al. LATE-NC staging in routine neuropathologic diagnosis: an update. *Acta Neuropathol.* Feb 2023;145(2):159–173. doi:10.1007/s00401-022-02524-2

- 1 45. Robinson JL, Porta S, Garrett FG, et al. Limbic-predominant age-related TDP-43
2 encephalopathy differs from frontotemporal lobar degeneration. *Brain*. Sep 1 2020;143(9):2844–
3 2857. doi:10.1093/brain/awaa219
- 4 46. Young AL, Vogel JW, Robinson JL, et al. Data-driven neuropathological staging and
5 subtyping of TDP-43 proteinopathies. *Brain*. Jul 3 2023;146(7):2975–2988.
6 doi:10.1093/brain/awad145
- 7 47. Buccellato FR, D'Anca M, Tartaglia GM, Del Fabbro M, Galimberti D. Frontotemporal
8 dementia: from genetics to therapeutic approaches. *Expert Opin Investig Drugs*. Jun
9 2024;33(6):561–573. doi:10.1080/13543784.2024.2349286
- 10 48. Deleon J, Miller BL. Frontotemporal dementia. *Handb Clin Neurol*. 2018;148:409–430.
11 doi:10.1016/B978-0-444-64076-5.00027-2
- 12 49. Yang H, Kim D, Yang Y, Bagyinszky E, An SSA. TREM2 in Neurodegenerative
13 Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting. *Int J Mol Sci*. Jul 22
14 2025;26(15)doi:10.3390/ijms26157057
- 15 50. Olney NT, Spina S, Miller BL. Frontotemporal Dementia. *Neurol Clin*. May
16 2017;35(2):339–374. doi:10.1016/j.ncl.2017.01.008
- 17 51. Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. *Nat Rev*
18 *Dis Primers*. Aug 10 2023;9(1):40. doi:10.1038/s41572-023-00447-0
- 19 52. Snowden JS. Changing perspectives on frontotemporal dementia: A review. *J*
20 *Neuropsychol*. Jun 2023;17(2):211–234. doi:10.1111/jnp.12297
- 21 53. Del Campo M, Zetterberg H, Gandy S, et al. New developments of biofluid-based
22 biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. *Alzheimers*
23 *Dement*. Nov 2022;18(11):2292–2307. doi:10.1002/alz.12643
- 24 54. Donison N, Palik J, Volkening K, Strong MJ. Cellular and molecular mechanisms of
25 pathological tau phosphorylation in traumatic brain injury: implications for chronic traumatic
26 encephalopathy. *Mol Neurodegener*. May 10 2025;20(1):56. doi:10.1186/s13024-025-00842-z
- 27 55. Parra Bravo C, Naguib SA, Gan L. Cellular and pathological functions of tau. *Nat Rev Mol*
28 *Cell Biol*. Nov 2024;25(11):845–864. doi:10.1038/s41580-024-00753-9

- 1 56. Noble W, Hanger DP, Miller CC, Lovestone S. The importance of tau phosphorylation for
2 neurodegenerative diseases. *Front Neurol.* 2013;4:83. doi:10.3389/fneur.2013.00083
- 3 57. Brandt R, Trushina NI, Bakota L. Much More Than a Cytoskeletal Protein: Physiological
4 and Pathological Functions of the Non-microtubule Binding Region of Tau. *Front Neurol.*
5 2020;11:590059. doi:10.3389/fneur.2020.590059
- 6 58. Maina MB, Bailey LJ, Wagih S, et al. The involvement of tau in nucleolar transcription
7 and the stress response. *Acta Neuropathol Commun.* Jul 31 2018;6(1):70. doi:10.1186/s40478-
8 018-0565-6
- 9 59. Ulrich G, Salvade A, Boersema P, et al. Phosphorylation of nuclear Tau is modulated by
10 distinct cellular pathways. *Sci Rep.* Dec 7 2018;8(1):17702. doi:10.1038/s41598-018-36374-4
- 11 60. Tracy TE, Madero-Perez J, Swaney DL, et al. Tau interactome maps synaptic and
12 mitochondrial processes associated with neurodegeneration. *Cell.* Feb 17 2022;185(4):712–728
13 e14. doi:10.1016/j.cell.2021.12.041
- 14 61. Wang Y, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci.* Jan
15 2016;17(1):5–21. doi:10.1038/nrn.2015.1
- 16 62. Jeganathan S, von BM, Brutlach H, Steinhoff HJ, Mandelkow E. Global hairpin folding of
17 tau in solution. *Biochemistry.* 2/21/2006 2006;45(7):2283–2293. . doi:10.1021/bi0521543 [doi]
- 18 63. Mroczko B, Groblewska M, Litman-Zawadzka A. The Role of Protein Misfolding and Tau
19 Oligomers (TauOs) in Alzheimer's Disease (AD). *Int J Mol Sci.* Sep 20
20 2019;20(19)doi:10.3390/ijms20194661
- 21 64. Todd TW, Islam NN, Cook CN, Caulfield TR, Petrucelli L. Cryo-EM structures of
22 pathogenic fibrils and their impact on neurodegenerative disease research. *Neuron.* Jul 17
23 2024;112(14):2269–2288. doi:10.1016/j.neuron.2024.05.012
- 24 65. Creekmore BC, Watanabe R, Lee EB. Neurodegenerative Disease Tauopathies. *Annu Rev*
25 *Pathol.* Jan 24 2024;19:345–370. doi:10.1146/annurev-pathmechdis-051222-120750
- 26 66. Shi Y, Zhang W, Yang Y, et al. Structure-based classification of tauopathies. *Nature.* Oct
27 2021;598(7880):359–363. doi:10.1038/s41586-021-03911-7

67. Lo Cascio F, Park S, Sengupta U, et al. Brain-derived tau oligomer polymorphs: distinct aggregations, stability profiles, and biological activities. *Commun Biol.* Jan 15 2025;8(1):53. doi:10.1038/s42003-025-07499-w
68. Kumar M, Schlaffner CN, Tang S, et al. Molecular features of human pathological tau distinguish tauopathy-associated dementias. *Cell.* 2026/02/05/ 2026;189(3):956–968.e13. doi:10.1016/j.cell.2025.12.036
69. Mattsson-Carlgren N, Janelidze S, Bateman RJ, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. *EMBO Mol Med.* Jun 7 2021;13(6):e14022. doi:10.15252/emmm.202114022
70. Benussi A, Huber H, Tan K, et al. Plasma p-tau(217) and neurofilament/p-tau(217) ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration. *Alzheimers Dement.* Feb 2025;21(2):e14482. doi:10.1002/alz.14482
71. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA.* Aug 25 2020;324(8):772–781. doi:10.1001/jama.2020.12134
72. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. *JAMA Neurol.* Mar 1 2024;81(3):255–263. doi:10.1001/jamaneurol.2023.5319
73. Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. *Lancet Neurol.* Sep 2021;20(9):739–752. doi:10.1016/S1474-4422(21)00214-3
74. Hintermayer MA, Volkening K, Moszczynski AJ, Donison N, Strong MJ. Tau protein phosphorylation at Thr(175) initiates fibril formation via accessibility of the N-terminal phosphatase-activating domain. *J Neurochem.* Nov 2020;155(3):313–326. doi:10.1111/jnc.14942
75. Moszczynski AJ, Yang W, Hammond R, Ang LC, Strong MJ. Threonine175, a novel pathological phosphorylation site on tau protein linked to multiple tauopathies. *Acta Neuropathol Commun.* 1/11/2017 2017;5(1):6. . doi:10.1186/s40478-016-0406-4

- 1 76. Donison N, Hintermayer MA, Palik J, Fisher J, Volkening K, Strong MJ. MAPK family
2 members differentially regulate pThr175 tau-mediated pathogenicity. *Neurobiol Dis*. Dec 12
3 2025;107223. doi:10.1016/j.nbd.2025.107223
- 4 77. Strong MJ, Yang W, Strong WL, Leystra-Lantz C, Jaffe H, Pant HC. Tau protein
5 hyperphosphorylation in sporadic ALS with cognitive impairment. *Neurology*. 2006
6 2006;66(11):1770–1771. In File.
- 7 78. Behrouzi R, Liu X, Wu D, et al. Pathological tau deposition in Motor Neurone Disease and
8 frontotemporal lobar degeneration associated with TDP-43 proteinopathy. *Acta Neuropathol*
9 *Commun*. 2016 2016;4:33. . doi:10.1186/s40478-016-0301-z
- 10 79. Albayram O, Herbert MK, Kondo A, et al. Function and regulation of tau conformations
11 in the development and treatment of traumatic brain injury and neurodegeneration. *Cell Biosci*.
12 2016;6:59. doi:10.1186/s13578-016-0124-4
- 13 80. Qiu C, Li Z, Leigh DA, et al. The role of the Pin1-cis P-tau axis in the development and
14 treatment of vascular contribution to cognitive impairment and dementia and preeclampsia. *Front*
15 *Cell Dev Biol*. 2024;12:1343962. doi:10.3389/fcell.2024.1343962
- 16 81. Zhou XZ, Kops O, Werner A, et al. Pin1-dependent prolyl isomerization regulates
17 dephosphorylation of Cdc25C and tau proteins. *Mol Cell*. Oct 2000;6(4):873–83.
18 doi:10.1016/s1097-2765(05)00083-3
- 19 82. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function
20 of Alzheimer-associated phosphorylated tau protein. *Nature*. 6/24/1999 1999;399(6738):784–788.
21 doi:10.1038/21650
- 22 83. Kondo A, Shahpasand K, Mannix R, et al. Antibody against early driver of
23 neurodegeneration cis P-tau blocks brain injury and tauopathy. *Nature*. 7/23/2015
24 2015;523(7561):431–436. doi:10.1038/nature14658
- 25 84. Ashton NJ, Benedet AL, Pascoal TA, et al. Cerebrospinal fluid p-tau231 as an early
26 indicator of emerging pathology in Alzheimer's disease. *EBioMedicine*. Feb 2022;76:103836.
27 doi:10.1016/j.ebiom.2022.103836
- 28 85. Suarez-Calvet M, Karikari TK, Ashton NJ, et al. Novel tau biomarkers phosphorylated at
29 T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only

- 1 subtle changes in Abeta pathology are detected. *EMBO Mol Med.* Dec 7 2020;12(12):e12921.
2 doi:10.15252/emmm.202012921
- 3 86. Barthelemy NR, Bateman RJ, Hirtz C, et al. Cerebrospinal fluid phospho-tau T217
4 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET
5 amyloid-positive patient identification. *Alzheimers Res Ther.* Mar 17 2020;12(1):26.
6 doi:10.1186/s13195-020-00596-4
- 7 87. Mielke MM, Aakre JA, Algeciras-Schimmich A, et al. Comparison of CSF phosphorylated
8 tau 181 and 217 for cognitive decline. *Alzheimers Dement.* Apr 2022;18(4):602–611.
9 doi:10.1002/alz.12415
- 10 88. Martinez-Valbuena I, Lee S, Santamaria E, et al. 4R-tau seeding activity reveals molecular
11 subtypes in progressive supranuclear palsy. *Nat Commun.* Dec 31 2025;17(1):1006.
12 doi:10.1038/s41467-025-67744-y
- 13 89. Martinez-Valbuena I, Tartaglia MC, Fox SH, Lang AE, Kovacs GG. Four-Repeat Tau
14 Seeding in the Skin of Patients With Progressive Supranuclear Palsy. *JAMA Neurol.* Sep 23
15 2024;81(11):1228–30. doi:10.1001/jamaneurol.2024.3162
- 16 90. Strong MJ, Donison NS, Volkening K. Alterations in Tau Metabolism in ALS and ALS-
17 FTSD. *Front Neurol.* 2020;11:598907. doi:10.3389/fneur.2020.598907
- 18 91. Yang W, Sopper MM, Leystra-Lantz C, Strong MJ. Microtubule-associated tau protein
19 positive neuronal and glial inclusions in amyotrophic lateral sclerosis. *Neurology.* 2003
20 2003;61(12):1766–1773. In File.
- 21 92. Yang W, Strong MJ. Widespread neuronal and glial hyperphosphorylated tau deposition
22 in ALS with cognitive impairment. *Amyotroph Lateral Scler.* Feb 2012;13(2):178–93.
23 doi:10.3109/17482968.2011.622405
- 24 93. Moszczynski AJ, Strong W, Xu K, McKee A, Brown A, Strong MJ. Pathological Thr¹⁷⁵
25 tau phosphorylation in CTE and CTE with ALS. *Neurology.* 2018 2018;90(5):e380–e387. .
- 26 94. Bieniek KF, Cairns NJ, Crary JF, et al. The Second NINDS/NIBIB Consensus Meeting to
27 Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. *J*
28 *Neuropathol Exp Neurol.* Feb 22 2021;80(3):210–219. doi:10.1093/jnen/nlab001

95. McKee AC, Stein TD, Huber BR, et al. Chronic traumatic encephalopathy (CTE): criteria for neuropathological diagnosis and relationship to repetitive head impacts. *Acta Neuropathol.* Apr 2023;145(4):371–394. doi:10.1007/s00401-023-02540-w
96. Tanaka H, Black LE, Forrest SL, et al. Spinal Cord Tau and Protein Copathologies Associated With Chronic Traumatic Encephalopathy. *JAMA Neurol.* Jan 26 2026;doi:10.1001/jamaneurol.2025.5421
97. Stevens CH, Guthrie NJ, van Roijen M, Halliday GM, Ooi L. Increased Tau Phosphorylation in Motor Neurons From Clinically Pure Sporadic Amyotrophic Lateral Sclerosis Patients. *J Neuropathol Exp Neurol.* Jul 1 2019;78(7):605–614. doi:10.1093/jnen/nlz041
98. Sanghai N, Barzegar Behrooz A, Latifi-Navid H, Fahanik Babaei J, Tranmer GK. Phosphoproteomics-guided tau biomarker discovery in amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). *Front Neurosci.* 2025;19:1714196. doi:10.3389/fnins.2025.1714196
99. Cousins KAQ, Shaw LM, Shellikeri S, et al. Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis. *Ann Neurol.* Nov 2022;92(5):807–818. doi:10.1002/ana.26462
100. Power MC, Mormino E, Soldan A, et al. Combined neuropathological pathways account for age-related risk of dementia. *Ann Neurol.* Jul 2018;84(1):10–22. doi:10.1002/ana.25246
101. Minogue G, Kawles A, Zouridakis A, et al. Distinct Patterns of Hippocampal Pathology in Alzheimer's Disease with Transactive Response DNA-binding Protein 43. *Ann Neurol.* Dec 2023;94(6):1036–1047. doi:10.1002/ana.26762
102. Tome SO, Tsaka G, Ronisz A, et al. TDP-43 pathology is associated with increased tau burdens and seeding. *Mol Neurodegener.* Sep 30 2023;18(1):71. doi:10.1186/s13024-023-00653-0
103. Moszczynski AJ, Harvey M, Fulcher N, et al. Synergistic toxicity in an in vivo model of neurodegeneration through the co-expression of human TDP-43(M337V) and tau(T175D) protein. *Acta Neuropathol Commun.* Nov 8 2019;7(1):170. doi:10.1186/s40478-019-0816-1
104. Aliakbari F, Volkening K, Nayeri Z, et al. Co-localization of tau and TDP-43 after extracellular vesicle delivery to cells. *The FEBS Journal.* 11/17 2025:n/a–n/a. doi:10.1111/febs.70336

- 1 105. Simonetti F, Zhong W, Hutten S, et al. Direct interaction between TDP-43 and Tau
2 promotes their co-condensation, while suppressing Tau fibril formation and seeding. *EMBO J.* Dec
3 2025;44(24):7395–7433. doi:10.1038/s44318-025-00590-2
- 4 106. Latimer CS, Stair JG, Hincks JC, et al. TDP-43 promotes tau accumulation and selective
5 neurotoxicity in bigenic *Caenorhabditis elegans*. *Dis Model Mech.* Apr 1
6 2022;15(4):doi:10.1242/dmm.049323
- 7 107. Llamas-Rodriguez J, Oltmer J, Marshall M, Champion S, Frosch MP, Augustinack JC.
8 TDP-43 and tau concurrence in the entorhinal subfields in primary age-related tauopathy and
9 preclinical Alzheimer's disease. *Brain Pathol.* Jul 2023;33(4):e13159. doi:10.1111/bpa.13159
- 10 108. Chornenkyy Y, Fardo DW, Nelson PT. Tau and TDP-43 proteinopathies: kindred
11 pathologic cascades and genetic pleiotropy. *Lab Invest.* Jul 2019;99(7):993–1007.
12 doi:10.1038/s41374-019-0196-y
- 13 109. Josephs KA, Dickson DW, Tosakulwong N, et al. Rates of hippocampal atrophy and
14 presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective
15 study. *Lancet Neurol.* Nov 2017;16(11):917–924. doi:10.1016/S1474-4422(17)30284-3
- 16 110. Josephs KA, Whitwell JL, Weigand SD, et al. TDP-43 is a key player in the clinical features
17 associated with Alzheimer's disease. *Acta Neuropathol.* 2014;127(6):811–24.
18 doi:10.1007/s00401-014-1269-z
- 19 111. Kapasi A, Yu L, Boyle PA, Barnes LL, Bennett DA, Schneider JA. Limbic-predominant
20 age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging. *Neurology.*
21 Oct 6 2020;95(14):e1951–e1962. doi:10.1212/WNL.00000000000010454
- 22 112. James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43
23 stage, mixed pathologies, and clinical Alzheimer's-type dementia. *Brain.* Nov 1
24 2016;139(11):2983–2993. doi:10.1093/brain/aww224
- 25 113. Tome SO, Gomes LA, Li X, Vandenberghe R, Tousseyn T, Thal DR. TDP-43 interacts
26 with pathological tau protein in Alzheimer's disease. *Acta Neuropathol.* May 2021;141(5):795–
27 799. doi:10.1007/s00401-021-02295-2
- 28 114. Fawzi NL. Solid trouble: tau and TDP-43 interaction in aggregation and pathology. *EMBO*
29 *J.* Dec 2025;44(24):7327–7329. doi:10.1038/s44318-025-00646-3

115. Gu J, Chen F, Iqbal K, Gong CX, Wang X, Liu F. Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies. *J Biol Chem*. Jun 23 2017;292(25):10600–10612. doi:10.1074/jbc.M117.783498
116. Vu LT, Bowser R. Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. *Neurotherapeutics*. Jan 2017;14(1):119–134. doi:10.1007/s13311-016-0503-x
117. Kasai T, Kojima Y, Ohmichi T, et al. Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. *Ann Clin Transl Neurol*. Dec 2019;6(12):2489–2502. doi:10.1002/acn3.50943
118. Gambino CM, Ciaccio AM, Lo Sasso B, et al. The Role of TAR DNA Binding Protein 43 (TDP-43) as a Candidate Biomarker of Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. *Diagnostics (Basel)*. Jan 23 2023;13(3)doi:10.3390/diagnostics13030416
119. Bourbouli M, Rentzos M, Bougea A, et al. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. *Dement Geriatr Cogn Disord*. 2017;44(3-4):144–152. doi:10.1159/000478979
120. Thomas EV, Han C, Kim WJ, et al. ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression. *Ann Clin Transl Neurol*. Apr 2025;12(4):714–723. doi:10.1002/acn3.70001
121. Abu-Rumeileh S, Vacchiano V, Zenesini C, et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. *J Neurol*. Jun 2020;267(6):1699–1708. doi:10.1007/s00415-020-09761-z
122. Wilke C, Deuschle C, Rattay TW, Maetzler W, Synofzik M. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. *Neurobiol Aging*. Feb 2015;36(2):1072–4. doi:10.1016/j.neurobiolaging.2014.10.019
123. Grossman M, Elman L, McCluskey L, et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. *JAMA Neurol*. Apr 2014;71(4):442–8. doi:10.1001/jamaneurol.2013.6064

- 1 124. Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of
2 motoneuron diseases: a prospective study on 455 patients. *J Neurol Neurosurg Psychiatry*. Jan
3 2016;87(1):12–20. doi:10.1136/jnnp-2015-311387
- 4 125. Vacchiano V, Mastrangelo A, Zenesini C, et al. Elevated plasma p-tau181 levels unrelated
5 to Alzheimer's disease pathology in amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry*.
6 Jun 2023;94(6):428–435. doi:10.1136/jnnp-2022-330709
- 7 126. Meredith JE, Jr., Sankaranarayanan S, Guss V, et al. Characterization of novel CSF Tau
8 and ptau biomarkers for Alzheimer's disease. *PLoS One*. 2013;8(10):e76523.
9 doi:10.1371/journal.pone.0076523
- 10 127. Schreiber S, Spotorno N, Schreiber F, et al. Significance of CSF NfL and tau in ALS. *J*
11 *Neurol*. Nov 2018;265(11):2633–2645. doi:10.1007/s00415-018-9043-0
- 12 128. Benatar M, Wu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: A
13 candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. *Ann*
14 *Neurol*. Jul 2018;84(1):130–139. doi:10.1002/ana.25276
- 15 129. Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament
16 light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic
17 lateral sclerosis: A systematic review and meta-analysis. *Alzheimers Dement (Amst)*. Dec
18 2019;11:730–743. doi:10.1016/j.dadm.2019.08.009
- 19 130. Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early
20 symptom onset amyotrophic lateral sclerosis. *Neurology*. Jan 2 2018;90(1):e22–e30.
21 doi:10.1212/WNL.0000000000004761
- 22 131. Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: A prognostic
23 biomarker in amyotrophic lateral sclerosis. *Neurology*. Jun 2 2015;84(22):2247–57.
24 doi:10.1212/WNL.0000000000001642
- 25 132. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels
26 in neurodegenerative neurological diseases. *PLoS One*. 2013;8(9):e75091.
27 doi:10.1371/journal.pone.0075091

133. Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. *Neurology*. Jun 13 2017;88(24):2302–2309. doi:10.1212/WNL.0000000000004029
134. Shahim P, Norato G, Sinaii N, et al. Neurofilaments in Sporadic and Familial Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. *Genes (Basel)*. Apr 16 2024;15(4)doi:10.3390/genes15040496
135. Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nat Commun*. Jun 7 2021;12(1):3400. doi:10.1038/s41467-021-23620-z
136. Agah E, Mojtavavi H, Behkar A, et al. CSF and blood levels of Neurofilaments, T-Tau, P-Tau, and Abeta-42 in amyotrophic lateral sclerosis: a systematic review and meta-analysis. *J Transl Med*. Oct 21 2024;22(1):953. doi:10.1186/s12967-024-05767-7
137. Obara K, Ito D, Nilsson C, et al. Diagnostic and Prognostic Value of Blood and Cerebrospinal Fluid Biomarkers in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. *Eur J Neurol*. Oct 2025;32(10):e70382. doi:10.1111/ene.70382
138. Muqaku B, Dorst J, Wiesenfarth M, Otto M, Ludolph AC, Oeckl P. Peptidomic analysis of CSF reveals new biomarker candidates for amyotrophic lateral sclerosis. *EMBO Mol Med*. Aug 2025;17(8):1926–1949. doi:10.1038/s44321-025-00272-w
139. Brodovitch A, Boucraut J, Delmont E, et al. Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS. *Sci Rep*. Jan 12 2021;11(1):703. doi:10.1038/s41598-020-80370-6
140. Verde F. Neurochemical biomarkers of amyotrophic lateral sclerosis: recent developments. *Curr Opin Neurol*. Oct 1 2025;38(5):614–619. doi:10.1097/WCO.0000000000001411
141. Saracino D, Dorgham K, Camuzat A, et al. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications. *J Neurol Neurosurg Psychiatry*. Dec 2021;92(12):1278–1288. doi:10.1136/jnnp-2021-326914
142. Verde F, Otto M, Silani V. Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. *Front Neurosci*. 2021;15:679199. doi:10.3389/fnins.2021.679199

143. De Schaepdryver M, Goossens J, De Meyer S, et al. Serum neurofilament heavy chains as early marker of motor neuron degeneration. *Ann Clin Transl Neurol*. Oct 2019;6(10):1971–1979. doi:10.1002/acn3.50890
144. De Schaepdryver M, Jeromin A, Gille B, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry*. Apr 2018;89(4):367–373. doi:10.1136/jnnp-2017-316605
145. Illan-Gala I, Alcolea D, Montal V, et al. CSF sAPPbeta, YKL-40, and NfL along the ALS-FTD spectrum. *Neurology*. Oct 23 2018;91(17):e1619–e1628. doi:10.1212/WNL.0000000000006383
146. Steinacker P, Verde F, Fang L, et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. *J Neurol Neurosurg Psychiatry*. Mar 2018;89(3):239–247. doi:10.1136/jnnp-2017-317138
147. Thompson AG, Gray E, Bampton A, Raciborska D, Talbot K, Turner MR. CSF chitinase proteins in amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry*. Nov 2019;90(11):1215–1220. doi:10.1136/jnnp-2019-320442
148. Thompson AG, Gray E, Thezenas ML, et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. *Ann Neurol*. Feb 2018;83(2):258–268. doi:10.1002/ana.25143
149. Cooper-Knock J, Green C, Altschuler G, et al. A data-driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis. *Acta Neuropathol Commun*. Mar 16 2017;5(1):23. doi:10.1186/s40478-017-0424-x
150. Weydt P, Oeckl P, Huss A, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. *Ann Neurol*. Jan 2016;79(1):152–8. doi:10.1002/ana.24552
151. Benatar M, Wu J, Lombardi V, et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype. *Amyotroph Lateral Scler Frontotemporal Degener*. Nov 2019;20(7-8):538–548. doi:10.1080/21678421.2019.1646769

- 1 152. Lu CH, Petzold A, Topping J, et al. Plasma neurofilament heavy chain levels and disease
2 progression in amyotrophic lateral sclerosis: insights from a longitudinal study. *J Neurol*
3 *Neurosurg Psychiatry*. May 2015;86(5):565–73. doi:10.1136/jnnp-2014-307672
- 4 153. Lu CH, Kalmar B, Malaspina A, Greensmith L, Petzold A. A method to solubilise protein
5 aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect. *J*
6 *Neurosci Methods*. Feb 15 2011;195(2):143–50. doi:10.1016/j.jneumeth.2010.11.026
- 7 154. Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts
8 neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. *Nat Med*. Feb
9 2019;25(2):277–283. doi:10.1038/s41591-018-0304-3
- 10 155. van der Ende EL, Meeter LH, Poos JM, et al. Serum neurofilament light chain in genetic
11 frontotemporal dementia: a longitudinal, multicentre cohort study. *Lancet Neurol*. Dec
12 2019;18(12):1103–1111. doi:10.1016/S1474-4422(19)30354-0
- 13 156. Sleegers K, Brouwers N, Van Damme P, et al. Serum biomarker for progranulin-associated
14 frontotemporal lobar degeneration. *Ann Neurol*. May 2009;65(5):603–9. doi:10.1002/ana.21621
- 15 157. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels
16 predict progranulin mutations in frontotemporal lobar degeneration. *Neurology*. Oct 14
17 2008;71(16):1235–9. doi:10.1212/01.wnl.0000325058.10218.fc
- 18 158. Goossens J, Bjerke M, Van Mossevelde S, et al. Diagnostic value of cerebrospinal fluid
19 tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. *Alzheimers Res*
20 *Ther*. Mar 20 2018;10(1):31. doi:10.1186/s13195-018-0364-0
- 21 159. Chouliaras L, Thomas A, Malpetti M, et al. Differential levels of plasma biomarkers of
22 neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and
23 progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry*. Jun 2022;93(6):651–658.
24 doi:10.1136/jnnp-2021-327788
- 25 160. Lantero Rodriguez J, Karikari TK, Suarez-Calvet M, et al. Plasma p-tau181 accurately
26 predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the
27 clinical characterisation of cognitive decline. *Acta Neuropathol*. Sep 2020;140(3):267–278.
28 doi:10.1007/s00401-020-02195-x

- 1 161. Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker
2 for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from
3 four prospective cohorts. *Lancet Neurol.* May 2020;19(5):422–433. doi:10.1016/S1474-
4 4422(20)30071-5
- 5 162. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease:
6 relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal
7 progression to Alzheimer's dementia. *Nat Med.* Mar 2020;26(3):379–386. doi:10.1038/s41591-
8 020-0755-1
- 9 163. de Jong D, Jansen RW, Pijnenburg YA, et al. CSF neurofilament proteins in the differential
10 diagnosis of dementia. *J Neurol Neurosurg Psychiatry.* Sep 2007;78(9):936–8.
11 doi:10.1136/jnnp.2006.107326
- 12 164. Landqvist Waldo M, Frizell Santillo A, Passant U, et al. Cerebrospinal fluid neurofilament
13 light chain protein levels in subtypes of frontotemporal dementia. *BMC Neurol.* May 29
14 2013;13:54. doi:10.1186/1471-2377-13-54
- 15 165. Brettschneider J, Petzold A, Schottle D, Claus A, Riepe M, Tumani H. The neurofilament
16 heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease. *Dement Geriatr*
17 *Cogn Disord.* 2006;21(5-6):291–5. doi:10.1159/000091436
- 18 166. Borroni B, Benussi A, Archetti S, et al. Csf p-tau181/tau ratio as biomarker for TDP
19 pathology in frontotemporal dementia. *Amyotroph Lateral Scler Frontotemporal Degener.* Mar
20 2015;16(1-2):86–91. doi:10.3109/21678421.2014.971812
- 21 167. Hu WT, Watts K, Grossman M, et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker
22 for FTLTD-TDP. *Neurology.* Nov 26 2013;81(22):1945–52.
23 doi:10.1212/01.wnl.0000436625.63650.27
- 24 168. Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE.
25 Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and
26 neurofilaments for frontotemporal dementia subtypes. *Alzheimers Dement (Amst).* Dec
27 2015;1(4):505–12. doi:10.1016/j.dadm.2015.11.001

169. Durcan R, Heslegrave A, Swann P, et al. Novel blood-based proteomic signatures across multiple neurodegenerative diseases. *Alzheimers Dement.* Mar 2025;21(3):e70116. doi:10.1002/alz.70116
170. Irwin DJ, Lleo A, Xie SX, et al. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. *Ann Neurol.* Aug 2017;82(2):247–258. doi:10.1002/ana.24996
171. Obrocki P, Khatun A, Ness D, et al. Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg. *Alzheimers Res Ther.* Feb 28 2020;12(1):20. doi:10.1186/s13195-020-00586-6
172. Gabelle A, Roche S, Geny C, et al. Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia. *J Alzheimers Dis.* 2011;26(3):553–63. doi:10.3233/JAD-2011-110515
173. Meeter LHH, Vijverberg EG, Del Campo M, et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. *Neurology.* Apr 3 2018;90(14):e1231–e1239. doi:10.1212/WNL.0000000000005261
174. Cousins KAQ, Phillips JS, Irwin DJ, et al. ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. *Alzheimers Dement.* May 2021;17(5):822–830. doi:10.1002/alz.12233
175. Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. *Nat Med.* Mar 2020;26(3):387–397. doi:10.1038/s41591-020-0762-2
176. Liu E, Jones SL, Light V, et al. Accuracy of blood-based neurofilament light to different genetic frontotemporal dementia from primary psychiatric disorders. *J Alzheimers Dis.* Aug 2025;106(4):1337–1354. doi:10.1177/13872877251352103
177. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. *Ann Neurol.* Jan 2014;75(1):116–26. doi:10.1002/ana.24052

- 1 178. Oeckl P, Anderl-Straub S, Danek A, et al. Relationship of serum beta-synuclein with blood
2 biomarkers and brain atrophy. *Alzheimers Dement.* Apr 2023;19(4):1358–1371.
3 doi:10.1002/alz.12790
- 4 179. Steinacker P, Anderl-Straub S, Diehl-Schmid J, et al. Serum neurofilament light chain in
5 behavioral variant frontotemporal dementia. *Neurology.* Oct 9 2018;91(15):e1390–e1401.
6 doi:10.1212/WNL.0000000000006318
- 7 180. Rojas JC, Wang P, Staffaroni AM, et al. Plasma Neurofilament Light for Prediction of
8 Disease Progression in Familial Frontotemporal Lobar Degeneration. *Neurology.* May 4
9 2021;96(18):e2296–e2312. doi:10.1212/WNL.00000000000011848
- 10 181. Sogorb-Esteve A, Weiner S, Simren J, et al. Proteomic analysis reveals distinct
11 cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes. *Sci Transl Med.*
12 Feb 5 2025;17(784):eadm9654. doi:10.1126/scitranslmed.adm9654
- 13 182. Staffaroni AM, Quintana M, Wendelberger B, et al. Temporal order of clinical and
14 biomarker changes in familial frontotemporal dementia. *Nat Med.* Oct 2022;28(10):2194–2206.
15 doi:10.1038/s41591-022-01942-9
- 16 183. Mattsson-Carlsson N, Grinberg LT, Boxer A, et al. Cerebrospinal Fluid Biomarkers in
17 Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. *Neurology.* Mar
18 15 2022;98(11):e1137–e1150. doi:10.1212/WNL.00000000000200040
- 19 184. Woollacott IOC, Nicholas JM, Heslegrave A, et al. Cerebrospinal fluid soluble TREM2
20 levels in frontotemporal dementia differ by genetic and pathological subgroup. *Alzheimers Res*
21 *Ther.* Aug 16 2018;10(1):79. doi:10.1186/s13195-018-0405-8
- 22 185. Escal J, Fourier A, Formaglio M, et al. Comparative diagnosis interest of NfL and pNfH in
23 CSF and plasma in a context of FTD-ALS spectrum. *J Neurol.* Mar 2022;269(3):1522–1529.
24 doi:10.1007/s00415-021-10714-3
- 25 186. Cousins KAQ, Shaw LM, Chen-Plotkin A, et al. Distinguishing Frontotemporal Lobar
26 Degeneration Tau From TDP-43 Using Plasma Biomarkers. *JAMA Neurol.* Nov 1
27 2022;79(11):1155–1164. doi:10.1001/jamaneurol.2022.3265

- 1 187. Estades Ayuso V, Pickles S, Todd T, et al. TDP-43-regulated cryptic RNAs accumulate in
2 Alzheimer's disease brains. *Mol Neurodegener.* Aug 21 2023;18(1):57. doi:10.1186/s13024-023-
3 00646-z
- 4 188. Mehta PR, Brown AL, Ward ME, Fratta P. The era of cryptic exons: implications for ALS-
5 FTD. *Mol Neurodegener.* Mar 15 2023;18(1):16. doi:10.1186/s13024-023-00608-5
- 6 189. Liang T, Wu Z, Li J, Wu S, Shi W, Wang L. The emerging double-edged sword role of
7 exosomes in Alzheimer's disease. *Front Aging Neurosci.* 2023;15:1209115.
8 doi:10.3389/fnagi.2023.1209115
- 9 190. Zhou W, Zhao L, Mao Z, Wang Z, Zhang Z, Li M. Bidirectional Communication Between
10 the Brain and Other Organs: The Role of Extracellular Vesicles. *Cell Mol Neurobiol.* Aug
11 2023;43(6):2675–2696. doi:10.1007/s10571-023-01345-5
- 12 191. Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of
13 extracellular vesicles (MISEV2023): From basic to advanced approaches. *J Extracell Vesicles.*
14 Feb 2024;13(2):e12404. doi:10.1002/jev2.12404
- 15 192. Rajendran L, Honsho M, Zahn TR, et al. Alzheimer's disease beta-amyloid peptides are
16 released in association with exosomes. *Proc Natl Acad Sci U S A.* Jul 25 2006;103(30):11172–7.
17 doi:10.1073/pnas.0603838103
- 18 193. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the
19 mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol.* Apr 2011;29(4):341–5.
20 doi:10.1038/nbt.1807
- 21 194. Feneberg E, Steinacker P, Lehnert S, et al. Limited role of free TDP-43 as a diagnostic tool
22 in neurodegenerative diseases. *Amyotroph Lateral Scler Frontotemporal Degener.* Sep 2014;15(5-
23 6):351–6. doi:10.3109/21678421.2014.905606
- 24 195. Asai H, Ikezu S, Tsunoda S, et al. Depletion of microglia and inhibition of exosome
25 synthesis halt tau propagation. *Nat Neurosci.* Nov 2015;18(11):1584–93. doi:10.1038/nn.4132
- 26 196. Aliakbari F, Stocck NB, Cole-Andre M, et al. A methodological primer of extracellular
27 vesicles isolation and characterization via different techniques. *Biol Methods Protoc.*
28 2024;9(1):bpae009. doi:10.1093/biomethods/bpae009

197. Iguchi Y, Eid L, Parent M, et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. *Brain*. Dec 2016;139(Pt 12):3187–3201. doi:10.1093/brain/aww237
198. Yuyama K, Igarashi Y. Exosomes as Carriers of Alzheimer's Amyloid-ss. *Front Neurosci*. 2017;11:229. doi:10.3389/fnins.2017.00229
199. Melachroinou K, Divolis G, Tsafaras G, et al. Endogenous Alpha-Synuclein is Essential for the Transfer of Pathology by Exosome-Enriched Extracellular Vesicles, Following Inoculation with Preformed Fibrils in vivo. *Aging Dis*. Apr 1 2024;15(2):869–892. doi:10.14336/AD.2023.0614
200. Zhao Y, Gu Y, Zhang Q, Liu H, Liu Y. The Potential Roles of Exosomes Carrying APP and Tau Cleavage Products in Alzheimer's Disease. *J Clin Med*. Feb 27 2023;12(5)doi:10.3390/jcm12051883
201. Holmes BB, Furman JL, Mahan TE, et al. Proteopathic tau seeding predicts tauopathy in vivo. *Proc Natl Acad Sci U S A*. Oct 14 2014;111(41):E4376–85. doi:10.1073/pnas.1411649111
202. Polanco JC, Scieluna BJ, Hill AF, Gotz J. Extracellular Vesicles Isolated from the Brains of rTg4510 Mice Seed Tau Protein Aggregation in a Threshold-dependent Manner. *J Biol Chem*. Jun 10 2016;291(24):12445–12466. doi:10.1074/jbc.M115.709485
203. Sproviero D, La Salvia S, Giannini M, et al. Pathological Proteins Are Transported by Extracellular Vesicles of Sporadic Amyotrophic Lateral Sclerosis Patients. *Front Neurosci*. 2018;12:487. doi:10.3389/fnins.2018.00487
204. Otake K, Kamiguchi H, Hirozane Y. Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid. *BMC Med Genomics*. Jan 10 2019;12(1):7. doi:10.1186/s12920-019-0473-z
205. Chatterjee M, Ozdemir S, Fritz C, et al. Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. *Nat Med*. Jun 2024;30(6):1771–1783. doi:10.1038/s41591-024-02937-4
206. Pasetto L, Callegaro S, Corbelli A, et al. Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis. *Mol Neurodegener*. Aug 10 2021;16(1):52. doi:10.1186/s13024-021-00470-3

207. Hawley ZCE, Campos-Melo D, Droppelmann CA, Strong MJ. MotomiRs: miRNAs in
motor neuron function and disease. *Front Mol Neurosci.* 2017 2017;10:127.
doi:10.3389/fnmol.2017.00127
208. Hawley ZCE, Campos-Melo D, Strong MJ. Evidence of a negative feedback network
between TDP-43 and miRNAs dependent on TDP-43 nuclear localization. *J Mol Biol.* Dec 4
2020;432(24):166695. doi:10.1016/j.jmb.2020.10.029
209. Campos-Melo D, Droppelmann CA, He Z, Volkening K, Strong MJ. Altered microRNA
expression profile in Amyotrophic Lateral Sclerosis: a role in the regulation of NFL mRNA levels.
Mol Brain. 2013 2013;6:26. doi:1756-6606-6-26
210. Banack SA, Dunlop RA, Mehta P, et al. A microRNA diagnostic biomarker for
amyotrophic lateral sclerosis. *Brain Commun.* 2024;6(5):fcae268.
doi:10.1093/braincomms/fcae268
211. Banack SA, Dunlop RA, Cox PA. An miRNA fingerprint using neural-enriched
extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral
sclerosis/motor neuron disease. *Open Biol.* Jun 2020;10(6):200116. doi:10.1098/rsob.200116
212. Banack SA, Dunlop RA, Stommel EW, Mehta P, Cox PA. miRNA extracted from
extracellular vesicles is a robust biomarker of amyotrophic lateral sclerosis. *J Neurol Sci.* Nov 15
2022;442:120396. doi:10.1016/j.jns.2022.120396
213. Dunlop RA, Cox PA, Mehta P, Stommel EW, Banack SA. miRNA Biomarkers Diagnose
Amyotrophic Lateral Sclerosis in Circulating Blood. *Mol Neurobiol.* Dec 16 2025;63(1):298.
doi:10.1007/s12035-025-05579-w
214. Kim JA, Park C, Sung JJ, Seo DJ, Choi SJ, Hong YH. Small RNA sequencing of circulating
small extracellular vesicles microRNAs in patients with amyotrophic lateral sclerosis. *Sci Rep.*
Apr 4 2023;13(1):5528. doi:10.1038/s41598-023-32717-y
215. Rizzuti M, Melzi V, Gagliardi D, et al. Insights into the identification of a molecular
signature for amyotrophic lateral sclerosis exploiting integrated microRNA profiling of iPSC-
derived motor neurons and exosomes. *Cell Mol Life Sci.* Mar 14 2022;79(3):189.
doi:10.1007/s00018-022-04217-1

- 1 216. Freischmidt A, Muller K, Zondler L, et al. Serum microRNAs in patients with genetic
2 amyotrophic lateral sclerosis and pre-manifest mutation carriers. *Brain*. Nov 2014;137(Pt
3 11):2938–50. doi:10.1093/brain/awu249
- 4 217. Dobrowolny G, Martone J, Lepore E, et al. A longitudinal study defined circulating
5 microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients.
6 *Cell Death Discov*. Jan 11 2021;7(1):4. doi:10.1038/s41420-020-00397-6
- 7 218. Schellnegger M, Hofmann E, Carnieletto M, Kamolz LP. Unlocking longevity: the role of
8 telomeres and its targeting interventions. *Front Aging*. 2024;5:1339317.
9 doi:10.3389/fragi.2024.1339317
- 10 219. Martinez P, Blasco MA. Replicating through telomeres: a means to an end. *Trends*
11 *Biochem Sci*. Sep 2015;40(9):504–15. doi:10.1016/j.tibs.2015.06.003
- 12 220. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging.
13 *Cell*. Jun 6 2013;153(6):1194–217. doi:10.1016/j.cell.2013.05.039
- 14 221. Muzumdar R, Atzmon G. Telomere length and aging. *Reviews on Selected Topics of*
15 *Telomere Biology*. 2012;1:3–30. doi:10.5772/53227
- 16 222. Manjaly ZR, Scott KM, Abhinav K, et al. The sex ratio in amyotrophic lateral sclerosis: A
17 population based study. *Amyotroph Lateral Scler*. Oct 2010;11(5):439–42.
18 doi:10.3109/17482961003610853
- 19 223. Trojsi F, D'Alvano G, Bonavita S, Tedeschi G. Genetics and Sex in the Pathogenesis of
20 Amyotrophic Lateral Sclerosis (ALS): Is There a Link? *Int J Mol Sci*. May 21
21 2020;21(10)doi:10.3390/ijms21103647
- 22 224. Zamani A, Thomas E, Wright DK. Sex biology in amyotrophic lateral sclerosis. *Ageing*
23 *Res Rev*. Mar 2024;95:102228. doi:10.1016/j.arr.2024.102228
- 24 225. Gardner M, Bann D, Wiley L, et al. Gender and telomere length: systematic review and
25 meta-analysis. *Exp Gerontol*. Mar 2014;51:15–27. doi:10.1016/j.exger.2013.12.004
- 26 226. Al Khleifat A, Iacoangeli A, Jones AR, et al. Telomere length analysis in amyotrophic
27 lateral sclerosis using large-scale whole genome sequence data. *Front Cell Neurosci*.
28 2022;16:1050596. doi:10.3389/fncel.2022.1050596

- 1 227. Al Khleifat A, Iacoangeli A, Shatunov A, et al. Telomere length is greater in ALS than in
2 controls: a whole genome sequencing study. *Amyotroph Lateral Scler Frontotemporal Degener.*
3 May 2019;20(3-4):229–234. doi:10.1080/21678421.2019.1586951
- 4 228. Telomeres Mendelian Randomization C, Haycock PC, Burgess S, et al. Association
5 Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian
6 Randomization Study. *JAMA Oncol.* May 1 2017;3(5):636–651.
7 doi:10.1001/jamaoncol.2016.5945
- 8 229. Kim EJ, Koh SH, Ha J, et al. Increased telomere length in patients with frontotemporal
9 dementia syndrome. *J Neurol Sci.* Sep 15 2021;428:117565. doi:10.1016/j.jns.2021.117565
- 10 230. Rodriguez-Fernandez B, Gispert JD, Guigo R, Navarro A, Vilor-Tejedor N, Crous-Bou M.
11 Genetically predicted telomere length and its relationship with neurodegenerative diseases and life
12 expectancy. *Comput Struct Biotechnol J.* 2022;20:4251–4256. doi:10.1016/j.csbj.2022.08.006
- 13 231. Gao Y, Wang T, Yu X, International FTDGC, Zhao H, Zeng P. Mendelian randomization
14 implies no direct causal association between leukocyte telomere length and amyotrophic lateral
15 sclerosis. *Sci Rep.* Jul 22 2020;10(1):12184. doi:10.1038/s41598-020-68848-9
- 16 232. Noches V, Campos-Melo D, Droppelmann CA, Strong MJ. Epigenetics in the formation
17 of pathological aggregates in amyotrophic lateral sclerosis. *Front Mol Neurosci.*
18 2024;17:1417961. doi:10.3389/fnmol.2024.1417961
- 19 233. Hou X, Jiang J, Deng M. Exploring epigenetic modifications as potential biomarkers and
20 therapeutic targets in amyotrophic lateral sclerosis. *J Neurol.* Apr 1 2025;272(4):304.
21 doi:10.1007/s00415-025-13028-w
- 22 234. Men J, Wang X, Zhou Y, et al. Neurodegenerative diseases: Epigenetic regulatory
23 mechanisms and therapeutic potential. *Cell Signal.* Jul 2025;131:111715.
24 doi:10.1016/j.celsig.2025.111715
- 25 235. Robertson KD. DNA methylation and human disease. *Nat Rev Genet.* Aug 2005;6(8):597–
26 610. doi:10.1038/nrg1655
- 27 236. Moore LD, Le T, Fan G. DNA methylation and its basic function.
28 *Neuropsychopharmacology.* Jan 2013;38(1):23–38. doi:10.1038/npp.2012.112

237. Coppede F, Stocco A, Mosca L, et al. Increase in DNA methylation in patients with amyotrophic lateral sclerosis carriers of not fully penetrant SOD1 mutations. *Amyotroph Lateral Scler Frontotemporal Degener.* Feb 2018;19(1-2):93–101. doi:10.1080/21678421.2017.1367401
238. Morahan JM, Yu B, Trent RJ, Pamphlett R. A genome-wide analysis of brain DNA methylation identifies new candidate genes for sporadic amyotrophic lateral sclerosis. *Amyotroph Lateral Scler.* Oct–Dec 2009;10(5-6):418–29. doi:10.3109/17482960802635397
239. Xi Z, Zhang M, Bruni AC, et al. The C9orf72 repeat expansion itself is methylated in ALS and FTLN patients. *Acta Neuropathol.* May 2015;129(5):715–27. doi:10.1007/s00401-015-1401-8
240. Gijssels I, Van Mossevelde S, van der Zee J, et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. *Mol Psychiatry.* Aug 2016;21(8):1112–24. doi:10.1038/mp.2015.159
241. Zhang M, Tartaglia MC, Moreno D, et al. DNA methylation age-acceleration is associated with disease duration and age at onset in C9orf72 patients. *Acta Neuropathol.* Aug 2017;134(2):271–279. doi:10.1007/s00401-017-1713-y
242. Pollard C, Saito E, Miller R, et al. Circulating Cell-Free DNA Methylation Profiles Enable Disease-Specific Detection of Alzheimer's, Parkinson's, and ALS from Blood. *medRxiv.* 2025:2025.10.07.25337503. doi:10.1101/2025.10.07.25337503
243. Niki P, Nalmpantis C, Ganbat J-O, et al. Human whole epigenome modelling for clinical applications with Pleiades. *bioRxiv.* 2025:2025.07.16.665231. doi:10.1101/2025.07.16.665231
244. Giannini LAA, Boers RG, van der Ende EL, et al. Distinctive cell-free DNA methylation characterizes presymptomatic genetic frontotemporal dementia. *Ann Clin Transl Neurol.* Mar 2024;11(3):744–756. doi:10.1002/acn3.51997
245. Brusati A, Peverelli S, Calzari L, et al. Exploring epigenetic drift and rare epivariations in amyotrophic lateral sclerosis by epigenome-wide association study. *Front Aging Neurosci.* 2023;15:1272135. doi:10.3389/fnagi.2023.1272135
246. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol.* 2013;14(10):R115. doi:10.1186/gb-2013-14-10-r115

- 1 247. Zhang M, McKeever PM, Xi Z, et al. DNA methylation age acceleration is associated with
2 ALS age of onset and survival. *Acta Neuropathol.* May 2020;139(5):943–946.
3 doi:10.1007/s00401-020-02131-z
- 4 248. Yang T, Xiao Y, Cheng Y, et al. Epigenetic clocks in neurodegenerative diseases: a
5 systematic review. *J Neurol Neurosurg Psychiatry.* Dec 2023;94(12):1064–1070.
6 doi:10.1136/jnnp-2022-330931
- 7 249. Marzi SJ, Leung SK, Ribarska T, et al. A histone acetylome-wide association study of
8 Alzheimer's disease identifies disease-associated H3K27ac differences in the entorhinal cortex.
9 *Nature Neuroscience.* 2018/11/01 2018;21(11):1618–1627. doi:10.1038/s41593-018-0253-7
- 10 250. Nativio R, Lan Y, Donahue G, et al. An integrated multi-omics approach identifies
11 epigenetic alterations associated with Alzheimer's disease. *Nat Genet.* Oct 2020;52(10):1024–
12 1035. doi:10.1038/s41588-020-0696-0
- 13 251. Toker L, Tran GT, Sundaresan J, et al. Genome-wide histone acetylation analysis reveals
14 altered transcriptional regulation in the Parkinson's disease brain. *Molecular Neurodegeneration.*
15 2021/05/05 2021;16(1):31. doi:10.1186/s13024-021-00450-7
- 16 252. Harrison IF, Smith AD, Dexter DT. Pathological histone acetylation in Parkinson's disease:
17 Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition. *Neurosci Lett.*
18 Feb 14 2018;666:48–57. doi:10.1016/j.neulet.2017.12.037
- 19 253. Tsalenchuk M, Farmer K, Castro S, et al. Unique nigral and cortical pathways implicated
20 by epigenomic and transcriptional analyses in rotenone Parkinson's model. *npj Parkinson's*
21 *Disease.* 2025/07/24 2025;11(1):217. doi:10.1038/s41531-025-01049-1
- 22 254. Tsalenchuk M, Gentleman SM, Marzi SJ. Linking environmental risk factors with
23 epigenetic mechanisms in Parkinson's disease. *npj Parkinson's Disease.* 2023/08/25
24 2023;9(1):123. doi:10.1038/s41531-023-00568-z
- 25 255. Wu H, Eckhardt CM, Baccarelli AA. Molecular mechanisms of environmental exposures
26 and human disease. *Nature Reviews Genetics.* 2023/05/01 2023;24(5):332–344.
27 doi:10.1038/s41576-022-00569-3
- 28 256. Newell ME, Aravindan A, Babbrah A, Halden RU. Epigenetic Biomarkers Driven by
29 Environmental Toxins Associated with Alzheimer's Disease, Parkinson's Disease, and

- 1 Amyotrophic Lateral Sclerosis in the United States: A Systematic Review. *Toxics*. Jan 31
2 2025;13(2)doi:10.3390/toxics13020114
- 3 257. Sebastiani P, Perls TT. The genetics of extreme longevity: lessons from the new England
4 centenarian study. *Front Genet*. 2012;3:277. doi:10.3389/fgene.2012.00277
- 5 258. Chatterjee N, Shi J, Garcia-Closas M. Developing and evaluating polygenic risk prediction
6 models for stratified disease prevention. *Nat Rev Genet*. Jul 2016;17(7):392–406.
7 doi:10.1038/nrg.2016.27
- 8 259. Bellou E, Stevenson-Hoare J, Escott-Price V. Polygenic risk and pleiotropy in
9 neurodegenerative diseases. *Neurobiol Dis*. Aug 2020;142:104953.
10 doi:10.1016/j.nbd.2020.104953
- 11 260. Tesi N, van der Lee S, Hulsman M, et al. Cognitively healthy centenarians are genetically
12 protected against Alzheimer's disease. *Alzheimers Dement*. Jun 2024;20(6):3864–3875.
13 doi:10.1002/alz.13810
- 14 261. Bellenguez C, Kucukali F, Jansen IE, et al. New insights into the genetic etiology of
15 Alzheimer's disease and related dementias. *Nat Genet*. Apr 2022;54(4):412–436.
16 doi:10.1038/s41588-022-01024-z
- 17 262. Van Deerlin VM, Sleiman PM, Martinez-Lage M, et al. Common variants at 7p21 are
18 associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nat Genet*. Mar
19 2010;42(3):234–9. doi:10.1038/ng.536
- 20 263. Nicholson AM, Rademakers R. What we know about TMEM106B in neurodegeneration.
21 *Acta Neuropathol*. Nov 2016;132(5):639–651. doi:10.1007/s00401-016-1610-9
- 22 264. Finch N, Carrasquillo MM, Baker M, et al. TMEM106B regulates progranulin levels and
23 the penetrance of FTLD in GRN mutation carriers. *Neurology*. Feb 1 2011;76(5):467–74.
24 doi:10.1212/WNL.0b013e31820a0e3b
- 25 265. Mirza SS, Pasternak M, Paterson AD, et al. Disease-modifying effects of TMEM106B in
26 genetic frontotemporal dementia: a longitudinal GENFI study. *Brain*. Aug 1 2025;148(8):2746–
27 2762. doi:10.1093/brain/awaf019

- 1 266. Pottier C, Kucukali F, Baker M, et al. Deciphering distinct genetic risk factors for FTL-
2 TDP pathological subtypes via whole-genome sequencing. *Nat Commun.* Apr 25 2025;16(1):3914.
3 doi:10.1038/s41467-025-59216-0
- 4 267. Ross JP, Akcimen F, Liao C, et al. Rare-variant and polygenic analyses of amyotrophic
5 lateral sclerosis in the French-Canadian genome. *Genet Med.* Jan 2024;26(1):100967.
6 doi:10.1016/j.gim.2023.100967
- 7 268. Dou J, Bakulski K, Guo K, et al. Cumulative Genetic Score and C9orf72 Repeat Status
8 Independently Contribute to Amyotrophic Lateral Sclerosis Risk in 2 Case-Control Studies.
9 *Neurol Genet.* Aug 2023;9(4):e200079. doi:10.1212/NXG.0000000000200079
- 10 269. van Rheen W, Shatunov A, Dekker AM, et al. Genome-wide association analyses
11 identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. *Nat Genet.*
12 Sep 2016;48(9):1043–8. doi:10.1038/ng.3622
- 13 270. Placek K, Benatar M, Wu J, et al. Machine learning suggests polygenic risk for cognitive
14 dysfunction in amyotrophic lateral sclerosis. *EMBO Mol Med.* Jan 11 2021;13(1):e12595.
15 doi:10.15252/emmm.202012595
- 16 271. Al-Chalabi A, Andrews J, Farhan S. Recent advances in the genetics of familial and
17 sporadic ALS. *Int Rev Neurobiol.* 2024;176:49–74. doi:10.1016/bs.irm.2024.04.007
- 18 272. Iacoangeli A, Dilliot AA, Al Khleifat A, et al. Oligogenic structure of amyotrophic lateral
19 sclerosis has genetic testing, counselling and therapeutic implications. *J Neurol Neurosurg*
20 *Psychiatry.* Sep 12 2025;96(10):928–936. doi:10.1136/jnnp-2024-335364
- 21 273. Pardo-Moreno T, Mohamed-Mohamed H, Suleiman-Martos S, et al. Amyotrophic Lateral
22 Sclerosis and Serum Lipid Level Association: A Systematic Review and Meta-Analytic Study. *Int*
23 *J Mol Sci.* May 12 2023;24(10)doi:10.3390/ijms24108675
- 24 274. Thompson AG, Marsden R, Talbot K, Turner MR. Primary care blood tests show lipid
25 profile changes in pre-symptomatic amyotrophic lateral sclerosis. *Brain Communications.*
26 2023;5(4)doi:10.1093/braincomms/fcad211
- 27 275. Vaage AM, Benth JS, Meyer HE, Holmoy T, Nakken O. Premorbid lipid levels and long-
28 term risk of ALS-a population-based cohort study. *Amyotroph Lateral Scler Frontotemporal*
29 *Degener.* May 2024;25(3-4):358–366. doi:10.1080/21678421.2023.2295455

- 1 276. González De Aguilar JL. Lipid Biomarkers for Amyotrophic Lateral Sclerosis. *Front*
2 *Neurol.* 2019;10:284. doi:10.3389/fneur.2019.00284
- 3 277. Skillback T, Farahmand B, Bartlett JW, et al. CSF neurofilament light differs in
4 neurodegenerative diseases and predicts severity and survival. *Neurology.* Nov 18
5 2014;83(21):1945–53. doi:10.1212/WNL.0000000000001015
- 6 278. Mukhija S, Hering L, Schreiner SJ, et al. Multimodal Biomarker Characterization of the
7 ALS/FTD Spectrum: A Real-World Clinical Dataset Analysis. *Int J Mol Sci.* Nov 27
8 2025;26(23)doi:10.3390/ijms262311496
- 9 279. van Veenhuijzen K, Tan HHG, Nitert AD, et al. Longitudinal Magnetic Resonance
10 Imaging in Asymptomatic C9orf72 Mutation Carriers Distinguishes Phenoconverters to
11 Amyotrophic Lateral Sclerosis or Amyotrophic Lateral Sclerosis With Frontotemporal Dementia.
12 *Ann Neurol.* Feb 2025;97(2):281–295. doi:10.1002/ana.27116
- 13 280. Feis RA, Bouts M, de Vos F, et al. A multimodal MRI-based classification signature
14 emerges just prior to symptom onset in frontotemporal dementia mutation carriers. *J Neurol*
15 *Neurosurg Psychiatry.* Nov 2019;90(11):1207–1214. doi:10.1136/jnnp-2019-320774
- 16 281. Feis RA, van der Grond J, Bouts M, et al. Classification using fractional anisotropy predicts
17 conversion in genetic frontotemporal dementia, a proof of concept. *Brain Commun.*
18 2020;2(2):fcaa079. doi:10.1093/braincomms/fcaa079
- 19 282. Jiskoot LC, Panman JL, Meeter LH, et al. Longitudinal multimodal MRI as prognostic and
20 diagnostic biomarker in presymptomatic familial frontotemporal dementia. *Brain.* Jan 1
21 2019;142(1):193–208. doi:10.1093/brain/awy288
- 22 283. Benatar M, Turner MR, Wu J. Presymptomatic amyotrophic lateral sclerosis: from
23 characterization to prevention. *Curr Opin Neurol.* Aug 1 2023;36(4):360–364.
24 doi:10.1097/wco.0000000000001168
- 25 284. Budelier MM, He Y, Barthelemy NR, et al. A map of neurofilament light chain species in
26 brain and cerebrospinal fluid and alterations in Alzheimer's disease. *Brain Commun.*
27 2022;4(2):fcac045. doi:10.1093/braincomms/fcac045

285. Benatar M, Wu J, McHutchison C, et al. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. *Brain*. Mar 29 2022;145(1):27–44. doi:10.1093/brain/awab404

Figure legends

Figure 1 Schematic illustration of TDP-43 structure and post-translational

modifications. (A) Prediction of intrinsic disorder tendency for full length TDP-43 (PrDOS; protein disorder prediction system [<https://prdos.hgc.jp/cgi-bin/top.cgi>] with prediction validated using UniProt (<https://www.uniprot.org>) based on Q13148 TADBP_Human]. Values of greater than 0.5 are indicative of being intrinsically disordered (unstructured). Typical of RNA binding proteins, both RRM1 and RRM2 are highly structured while virtually the entirety of the C-terminus domain (the glycine rich domain) is unstructured and capable of considerable flexibility. (B) Schematic illustration of full length TDP-43 including intrinsically disordered regions (IDR; yellow), RNA binding domains (RRM1 & 2; green); nuclear localization sequence (NLS; blue) and a putative nuclear export sequence (NES; blue). Posttranslational modifications are indicated according to the figure inset, while crucial phospho-epitopes observed in ALS tissues are noted. (C) Using AlphaFold3 and the Q13148 TDP-43 structure, the predicted structure for TDP-43 shows the highly structured N-terminus domain with RRM1 & RRM2 (green) in close approximation while the intrinsically disordered C-terminus [glycine-rich, Prion-like domain (PrLD)] is unstructured with the exception of an amyloidogenic α -helical segment. The majority of ALS-associated mutations are located within the PrDL 282-287.

Figure 2 Tau protein structure and assembly. (A) Tau protein, encoded by the MAPT gene (chromosome 17q21), is composed of four domains, including the N-terminal domain (spanning a.a 1-150), Proline-rich domain (a.a 151-243), Microtubule-binding domain (a.a 244-369), and C-terminal domain (a.a 370-441). Within the N-terminal domain are two N-terminal repeats, N1 and N2, which are encoded by exons 2 and 3, spanning a.a 45-103. The microtubule-binding domain consists of four imperfect repeats, R1-R4, encoded by exons 9-12, respectively. With respect to the longest tau isoform (2N4R), various epitopes are used as recognition sequences for utilization as diagnostic biomarkers, including the N-terminal and Microtubule-binding domain for t-tau, and pThr175, pThr181, pThr217, and pThr231 tau for phosphorylation-specific alterations. (B) In the human central nervous system, six unique isoforms of tau are produced through alternative splicing of exons 2, 3

and 10, resulting in isoforms varying with the inclusion and exclusion of the two N-terminal repeats and the second Microtubule-binding domain. In general, tau isoforms are classified as either 3R or 4R, based on the absence or presence of the second microtubule binding repeat. (C) The phosphorylation and assembly of pathogenic tau fibrils occur through an ordered process, beginning with the phosphorylation of microtubule-bound tau, leading to its dissociation from the microtubule and loss of structural integrity. Phosphorylated-unbound tau has an increased propensity to misfold and form soluble oligomers, which in turn leads to the aggregation of disease-specific protofilaments and fibrils. Created in BioRender. Donison, N. (2026) <https://BioRender.com/6kp89kl>.

Figure 3 Intersection of ALS-FTSD Pathobiology. (A) ALS, ALS-FTSD and FTD are characterized by regional brain atrophy compared to healthy controls. In ALS and FTD, evidence of frontal lobe atrophy is present, with the addition of temporal atrophy in FTD cases. (B) There is considerable overlap in the cellular mechanisms driving the progression of ALS-FTSD and FTD in the brain and spinal cord with aggregation of TDP-43 and tau in neuronal cytosol, leading to disruption of cellular homeostasis, synaptic dysfunction, and ultimately neuronal death. This process is reflected by the presence of a broad range of biomarkers, most commonly neurofilaments NFL and NFH in the CSF and blood. Disruption of RNA homeostasis is reflected by the presence of cryptic exon encoded peptides and miRNA species. A widespread neuroinflammatory response is defined by TREM2-positive microglia and GFAP-positive reactive astrocytes. Biomarkers in CSF or blood, either in isolation or contained within extracellular vesicles, include TDP-43, Tau, A β , NFL, NFH, CHI3L1, TREM2, GFAP, EVs, and mRNA, in addition to the absence of progranulin, is indicative of certain ALS-FTSD disease phenotypes. (C) In ALS-FTSD, progressive loss lower motor neurons in the brainstem and spinal cord often results in muscular atrophy, leading to clinical features of muscle weakness, and swallowing and speech impairments while upper motor neuron loss is reflected in spasticity. In affected neurons, nuclear TDP-43 depletion leads to the expression of cryptic exons and the production of cryptic proteins, which are often truncated or functionally altered. Recently, the presence of cryptic exons and proteins has been used as a biomarker for TDP-43 proteinopathies, including ALS-FTSD. Created in BioRender. Donison, N. (2026) <https://BioRender.com/u7m606a>.

Figure 4 The conceptual positioning of biotypic biomarkers. The progression of neurodegenerative diseases can be broadly characterized by a clinically manifest phase

1 that is readily recognized at the bedside and a presymptomatic phase that consists of both
2 a clinically silent and a prodromal phase as described by Benatar and colleagues^{283,285}. The
3 clinically silent phase can be further conceptualized by a “biologically at risk state” until its
4 transition to a “biologically active disease state”. Over time, the cumulative impact of the
5 neurodegenerative processes in this latter phase leads to phenotransition and heralds the
6 onset of the prodromal phase characterized by the insidious development of minimal
7 clinical deficits, in this case in the domains of motor (MMI), cognitive (MCI) and behavioural
8 (MBI). Ultimately, a threshold is reached beyond which further pathobiological progression
9 is accompanied by the emergence of a clinically manifest syndrome (the point of
10 phenoconversion). Disease progression in each phase and in each axis of neurological
11 impairment can be highly asynchronous and not necessarily co-existent (ie., in the case of
12 isolated motor degeneration in ALS without neuropsychological impairments). Biotypic
13 biomarkers (yellow highlight) occupy a unique niche in this conceptual timeline in being
14 agnostic to the specific underlying disease process. Such biomarkers reflect the
15 cumulative effect of a wide range of risk or susceptibility factors that drive the initiation of
16 the neurodegenerative process well before the period of phenotransition. Whether such
17 biotypic biomarkers can also be utilized to more robustly characterize the underlying
18 pathophysiology during the prodromal disease state through to clinically manifest disease
19 remains to be seen, although if so, reclassification as a diagnostic biomarker may be
20 considered.




Figure 1
201x229 mm (x DPI)




Figure 2
160x230 mm (x DPI)




Figure 3
160x230 mm (x DPI)




Figure 4
271x139 mm (x DPI)